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ABSTRACT  
 
Fibromyalgia Syndrome (FMS) is a chronic syndrome characterized by 
widespread pain. FMS is a collection of other symptoms and overlapping 
conditions contribute to complicate the diagnosis, the assessment and the 
treatment. Unknown etiology and none laboratory tests have been 
appropriately validated for the diagnosis of the disease. The comparison of 
protein patterns in body fluids of diseased and healthy subjects has the 
potential to identify new disease-specific biomarkers. Some purine 
nucleotide metabolism disorders such as myoadenylate deaminase (MAD) 
deficiency report symptoms similar to those seen in FMS. 
In consideration of what described above, we carried out a serum 
proteomic analysis of FMS patients with respect to control subjects 
searching potentially useful biomarkers for the disease. In addition, we 
evaluated serum purine metabolite concentrations in patients affected by 
FMS and the relationships between their levels and FMS clinical 
parameters. 
Twenty-two females affected by FMS (according to the American College 
of Rheumatology, 1990) and twenty-two healthy women were recruited as 
controls for analysis of purine metabolite. Sixteen females FMS and 
twelve controls were enrolled in the study for the analyses of the 
proteome. Proteomic analysis was performed by combining two-
dimensional gel electrophoresis (2-DE) and mass spectrometry (MS) and 
serum purine levels were quantified using reverse phase high performance 
liquid chromatographic (RP-HPLC).  
In our study, using the proteomic approach, we have identified 
differentially expressed proteins, such as Transthyretin (TTR), Alpha-1 
Antitrypsin (A1AT) and Retinol Binding Protein 4 (RBP4). The serum 
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concentrations of these proteins were significantly higher in FMS patients 
compared with healthy controls. TTR and RBP4 are retinoid transporters, 
moreover retinoid dysfunction is related to oxidative stress as well as 
A1AT. These results support the hypothesis that oxidative stress could be 
implicated in the pathophysiology of FMS.  
Moreover, considerably higher serum concentration of inosine, 
hypoxanthine and xanthine levels (p<0.001) and lower serum adenosine 
(p<0.05) were detected in the FMS patients when compared to healthy 
controls. Our data show a negative correlation between adenosine and the 
Fibromyalgia Impact Questionnaire (FIQ).  
Our results suggest that purines, in particular adenosine and inosine, may 
be involved in pain transmission in fibromyalgia.  
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SOMMARIO 
 
La sindrome fibromialgica (FMS) è caratterizzata da dolore diffuso 
cronico associato a un insieme di sintomi e condizioni sovrapposte che 
potrebbero contribuire a complicare la diagnosi, la valutazione e il 
trattamento della malattia. L'eziologia è sconosciuta e nessun esame di 
laboratorio è stato adeguatamente validato per la diagnosi e la gestione 
della malattia. Il confronto di pattern proteici nei fluidi biologici di 
pazienti e controlli potrebbe portare all’identificazione di specifici 
biomarcatori. Alcuni autori hanno riportato che alcune disfunzioni del 
metabolismo delle purine, come la carenza della mioadenilato deaminasi 
(MAD), determinano sintomi simili a quelli osservati nei pazienti 
fibromialgici.  
A seguito di queste considerazioni abbiamo effettuato un analisi del 
proteoma del siero di 16 pazienti affetti da FMS (secondo i criteri 
dell’American College of Rheumatology, 1990), confrontato con quello di 
12 soggetti sani, alla ricerca di potenziali biomarcatori. Inoltre, abbiamo 
determinato le concentrazioni sieriche di alcuni metaboliti purinici in 22 
pazienti affetti da FMS e 22 controlli e abbiamo valutato le relazioni tra i 
loro livelli e i sintomi della patologia. L’analisi proteomica è stata eseguita 
combinando l’elettroforesi bi-dimensionale (2-DE) e la spettrometria di 
massa (MS), mentre l’analisi dei metaboliti purinici è stata effettuata 
mediante una cromatografia liquida ad alta prestazione in fase inversa 
(RP-HPLC).  
L’analisi proteomica ha evidenziato la differente espressione di proteine 
come la Transtiretina (TTR), l’Alfa-1-Antitripsina (A1AT) e la proteina 
legante il retinolo (RBP4), nei soggetti affetti da FMS rispetto ai controlli. 
TTR e RBP4 sono trasportatori dei retinoidi; disfunzioni dei retinoidi e 
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dell’A1AT sono correlate allo stress ossidativo. I risultati ottenuti ci 
consentono di ipotizzare che lo stress ossidativo potrebbe essere coinvolto 
nella patofisiologia della FMS.  
L’analisi, mediante RP-HPLC, del siero di pazienti con FMS ha rilevato 
un aumento delle concentrazioni di inosina, ipoxantina e xantina 
(p<0.001) e valori significativamente bassi di adenosina (p<0.05) nei 
pazienti affetti da FMS rispetto ai controlli. I dati ottenuti mostrano una 
correlazione negativa tra adenosina e FIQ che potrebbe essere coerente 
con una maggiore sensibilità al dolore nei pazienti affetti da FMS. 
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1. INTRODUCTION 
 
1.1. Fibromyalgia 
 
1.1.1. Definition and epidemiology 
Fibromyalgia Syndrome (FMS) or fibromyalgia is the most common cause 
of widespread musculoskeletal pain (Wolfe F et al, 1990) and is a chronic 
condition causing pain, stiffness, and tenderness of the muscles, tendons, 
and joints. It is also characterized by restless sleep, tiredness, fatigue, 
anxiety, depression and disturbances in bowel function. 
In the past different terms were used to define what today is indicated as 
fibromyalgia. Fibromyalgia was previously referred as fibrositis, as 
suggested by William Gowers (Gowers WR, 1904) referring to regional 
pain syndromes associated with profound fatigue and sleep disturbance. 
Graham W in 1950 (Graham W, 1953) introduced the modern concept of 
fibromyalgia as “pain syndrome” in the absence of a specific organic 
disease. The term “fibromyalgia” was coined in the mid-1970s with the 
identification of extreme tenderness regions , the so-called “tender points”. 
The prevalence of FMS is estimated to range between 1.3% and 4.8% in 
the general population (Biewer W et al, 2004). 
Fibromyalgia affects approximately 6 million people in the United States 
(Sprott H, 2003), 85% to 92% are women (Lawrence RC et al, 1998; 
Wolfe F et al, 1990), many of whom are sedentary (Gowans SE et al, 
2004) and overweight or obese (Yunus MB et al, 2002). 
White KP et al (1999), in the London Fibromyalgia Epidemiology Study 
in Ontario, Canada, estimated the prevalence of FMS at 3.3% (4.9% in 
women versus 1.6% in men), and Branco JC, et al (2010) reported on a 
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multinational study of the prevalence of FMS in 5 European countries, 
estimating it at 4.7%. 
Häuser W and coworkers estimated the prevalence in Germany at 3.8%, 
with similar rates in men and women (Häuser W et al, 2009).  
In Italy affects at least 2% of the adult population (Salaffi F et al, 2005). 
However, it is still a poorly understood condition that is difficult to 
diagnose. 
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1.1.2. Symptoms 
FMS is a complex illness to diagnose and treat, with symptoms that may 
be part of, or overlap with other diseases or syndromes. 
FMS is one of the most common diseases affecting the muscles 
manifested with pain, stiffness and tenderness of the muscles, tendons and 
joints. Despite potentially disabling body pain, patients with fibromyalgia 
do not develop tissue damage or deformity (Mease P et al, 2007; Schmidt-
Wilcke T et al, 2011). The pain in fibromyalgia is generally widespread, 
involving both sides of the body. Pain usually affects neck, buttocks, 
shoulders, arms, upper back and chest. "Tender points" are localized 
tender areas of the body that can bring on widespread pain and muscle 
spasm when touched (Perrot S, 2008; Culpepper L, 2010). 
FMS typically presents in young or middle-aged females as persistent 
widespread pain, stiffness, fatigue and exhaustion, disrupted unrefreshing 
sleep, sleep disorders, restless sleep, awakening from sleep, difficulty in 
falling asleep and cognitive difficulties, often accompanied by multiple 
other unexplained symptoms, anxiety and/or depression, panic attacks, 
migraine/headache, gastrointestinal problems and functional impairment 
of daily living activities (Gerdle B et al, 2008; Wolfe F et al, 1995; Clauw 
DJ et al, 2003; Karakuş İ et al, 2004). A recent study reported that 88,9% 
of FMS patients have pain, 70.4% restless sleep, 88.9% fatigue and similar 
symptoms (Demirbağ B et al, 2012).  
Diagnosis is difficult and frequently overlooked because symptoms are 
vague and generalized. Despite this, three main symptoms are referred by 
almost every patient: pain, fatigue and sleep disturbance (Aaron LA et al, 
2000; Aaron LA et al, 2001). 
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Pain is the main symptom of FMS and it is known that many factors can 
influence soreness perception; there are discrepant findings related to 
vitamin D levels and pain intensity (De Rezende Pena C et al, 2010; 
Heidari B et al, 2010).  
Fatigue represents one of the most disabling symptoms associated with 
FMS, greatly impacting patients quality of life; sleep disturbance, such as 
difficulty falling asleep, frequent awakening during the night and early 
awakening with difficulty returning to sleep, are very commonly reported 
in persons with FMS.  
Recent years, two studies evaluated the concordance between subjective 
and objective methods of sleep assessment reporting that women with 
objective sleep deficits had significantly higher pain scores on the tender 
point index, perceived their sleep as significantly shoddier and reported 
significantly more depressive symptoms and more negative impact of 
FMS on daily life activities than those without deficit (Stuifbergen AK et 
al, 2010; Okifuji A et al, 2011). It is well known that FMS is frequently 
associated with psychiatric symptoms such as anxiety and depression; 
indeed some authors have argued the possibility of classifying this 
syndrome into affective spectrum disorders. 
Thyroid hormone levels are usually normal, even if the patients often 
show symptoms of hypothyroidism and there is some evidence suggesting 
an association with abnormal thyrotropin-releasing hormone (TRH) 
stimulation tests (Garrison L et al, 2003). 
Many conditions may be associated with fibromyalgia (Table 1): 
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Musculoskeletal  Genitourinary  Gastro intestinal  Miscellaneous  
• Nondermatomal 
paresthesia 
• Temporo 
mandibular joint 
syndrome  
• Hyper mobility 
syndrome  
• Restless legs 
syndrome  
• Rheumatoid 
arthritis 
• Systemic lupus 
erythematosus  
• Sjögren 
syndrome 
• Osteoarthritis  
• Chronic fatigue 
syndrome 
• Carpal tunnel 
syndrome  
• Myofascialpain 
syndrome  
• Dysmenorrhea  
• Interstitial 
cystitis  
• Vulvodynia  
• Female urethral 
syndrome  
• Vulvar 
vestibulitis  
• Premenstrual 
syndrome  
• Irritable bowel 
syndrome  
• Esophageal 
dysmotility  
• Tension/migraine 
headaches  
• Mitral valve 
prolapsed  
• Allergy  
• Vestibular disorders  
• Ocular disturbances  
• Anxiety disorders  
• Reynaud 
phenomenon  
• Thyroid dysfunction  
• Lyme disease 
• Hyperventilation  
• Cognitive 
dysfunction  
Table 1. Conditions associated with fibromyalgia (Tanriverdi F et al, 2007; Bradley 
LA, 2005; Woolf AD, 2000). 
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1.1.3. Etiopathogenesis 
The etiology and pathogenesis of fibromyalgia are still not fully 
understood but the current hypothesis is that FMS arises from interactions 
between the autonomic central nervous system, the hypothalamic-
pituitary-adrenal axis and the immune system (Clauw DJ et al 2011; 
Arnold LM, 2010; DeLeao JA et al, 2001; Buskila D, 2001). 
Central sensitization is considered the main mechanism involved and it is 
defined by the increased response to stimulation mediated by central 
nervous system (CNS) signaling (Yunus MB, 1992). Metabolic and 
pharmacologic findings suggest involvement of the CNS in FMS, such as 
alterations of N-methyl-D-aspartate receptors or monoaminergic 
modulation in the spinal cord (Russell IJ et al, 1994; Sörensen J et al, 
1997; Sörensen J et al, 1998; Graven–Nielsen T et al, 2000). 
Another proposed mechanism involves the well-known descending 
inhibitory pain pathways, which modulate spinal cord responses to painful 
stimuli. They seem to be impaired in patients with fibromyalgia, helping 
to exacerbate the central sensitization (Staud R et al, 2002; Staud R et al, 
2003; Kosek E et al, 1997). Glial cells activation appears to play an 
important role in the pathogenesis of fibromyalgia because they help to 
modulate pain transmission in the spinal cord. Activated by various 
painful stimuli, they release proinflammatory cytokines, nitric oxide, 
prostaglandins, and reactive oxygen species that stimulate and prolong 
spinal cord hyperexcitability (Watkins LR et al, 2001; Watkins LR et al, 
2005). As early as 1988, it was noted that aberrant expressions of immune 
mediators such as cytokines may contribute to the onset of disease 
symptoms (Wallace DJ et al, 1988). Wallace et al have been observed the 
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correlation between cytokines and several symptoms common in FMS 
(Wallace DJ et al, 2001). 
However, reports on changes in serum cytokine levels in FM patients have 
revealed conflicting results (Menzies V et al, 2010; Űceyler N et al, 2011). 
Recently Cordero MD et al (2013) showed in FMS high levels of serum 
TNF-alpha as a consequence of high cytokine levels, these data underline 
an important role of oxidative stress and mitochondrial dysfunction in the 
inflammatory process in several FMS patients, thus identifying a new 
subgroup of patients in FMS. 
Many evidence point out alterations in neurotransmitter systems in 
fibromyalgia, something which is interesting given that the main 
symptoms of fibromyalgia (that is, heightened pain perception, fatigue, 
sleep disorders and depressive- as well as anxiety-related symptoms) are 
closely related to neurotransmitters. 
In FMS patients, serotonin, dopamine and noradrenalin levels appear to be 
decreased, possibly contributing to dysfunctional descending pathways 
and resulting in attenuated descending inhibition (Becker S et al, 2012). 
Cerebrospinal fluid (CSF) concentrations of substance P and glutamate 
have been repeatedly found to be increased in fibromyalgia patients (Liu Z 
et al, 2000; Russell IJ et al, 1994; Vaerøy H et al, 1988).  
There is evidence for both a hypercortisolemic and hypocortisolemic state 
in FMS. In more detail, FMS patients have been reported to exhibit an 
elevated cortisol profile (Catley D et al, 2000), but also to display an 
attenuated cortisol response during the first hour after awakening 
(Weissbecker I et al, 2006; Klingmann PO et al, 2008). 
FM patients showed high values of adrenocorticotropic hormone (ACTH) 
both basally (Neeck G, 2000; Geenen R, 2002) and in response to stress, 
most likely as a consequence of a chronic hyposecretion of corticotropin-
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releasing hormone (CRH) (Griep EN et al, 1993). Growth hormone (GH) 
levels tend to be normal during the day, reduced during sleep because GH 
is mainly secreted during stage 4 of sleep and this phase is disrupted in 
patients affected by fibromyalgia; another these patients have high levels 
of somatostatin, a GH inhibitor, induced by ACTH whose levels are high 
as previously mentioned (Jones KD et al, 2007) but, recently, Kadetoff D 
et al (2010) found normal baseline ACTH and cortisol levels in patients 
with FMS.  
Thyroid hormone levels are usually normal, even if the patients often 
show symptoms of hypothyroidism and there is some evidence suggesting 
an association with abnormal thyrotropin-releasing hormone (TRH) 
stimulation tests (Garrison RL et al, 2003). Various studies (Cohen H et al, 
2001; Kooh M et al, 2003) seem to confirm that in fibromyalgia the 
sympathetic nervous system is persistently hyperactive, but hyporeactive 
to stress. This could explain some clinical symptoms such as fatigue, 
morning stiffness, sleep disorders, anxiety, pseudo-Raynaud’s 
phenomenon and bowel irritability (Stisi S et al, 2008). Furthermore 
patients with FMS often complain of sleep disorders. As revealed by 
electroencephalographic examinations the fourth phase of sleep is the 
most disturbed and a direct consequence should be a deficit of GH and 
insulin-like growth factor 1 (IGF-1) (Van Cauter E et al, 1998; Prinz PN et 
al, 1995), given that these hormones are involved in muscle microtrauma 
repair, the healing of this tissue could be affected by sleep disturbances 
(Bennett RM et al, 1992). Fibromyalgia is common in patients affected by 
autoimmune disease (Middleton GD et al, 1994; Wolfe F et al, 2004). 
Different studies in the literature deal with autoantibodies in fibromyalgia 
(Kӧtter I et al, 2007; Bazzichi L et al, 2007) with equivocal results.  
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The chronicity of FMS affects patients quality of life actions on their 
social relations, habits and routines, causing an increase in the 
psychological abnormalities common to FMS, especially depressive states 
and psychiatric disorders (Payne TC et al, 1982.). The prevalence of 
psychiatric conditions among patients affected by fibromyalgia is higher 
than among subjects complaining of other rheumatic diseases (Giesecke T 
et al, 2003). The most common disorders associated are anxiety, 
somatization, dysthymia, panic disorders, post-traumatic stress and overall 
depression (Epstein SA et al, 1999). Peripheral tissues such as skin, 
muscles, and microvessels are coming under closer investigation. 
Inadequate response to oxidative stress (Ozgocmen S et al, 2006), 
increased IL-1 in cutaneous tissues, increased substance P in muscles are 
all suspected to possibly play a role in this condition.  
Although the etiology of fibromyalgia remains unclear, it is believed that 
genetic and environmental factors may play significant roles in the 
development of fibromyalgia  
Genetic predisposition is likely to be an important factor as suggested by 
several familial studies (Buskila D et al, 2006) and transmission is thought 
to be polygenic (Buskila D et al, 2007). Among the various genes 
investigated, the most important are associated with neurotransmitters 
involved in pain transmission. A number of associations have been 
identified that including the serotonin 5-HT2A receptor polymorphism 
T/T phenotype, serotonin transporter, dopamine 4 receptor, and COMT 
(catechol-O-methyltransferase) polymorphism. Lee YH et al, (2012) 
demonstrates that the serotonin 2A (5-HT2A) receptor 102T/C 
polymorphism confers susceptibility to fibromyalgia, in contrast, no 
association was found between the serotonin transporter (5-HTT) gene-
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linked polymorphic region (5-HTTLPR) S/L allele, catechol-O-
methyltransferase (COMT) val158Met, and susceptibility to fibromyalgia. 
Recently, Arnold LM et al (2012) identify loci for fibromyalgia. This is 
the first study to report genome-wide suggestive linkage of fibromyalgia 
to the chromosome 17p11.2-q11.2 region. It is notable that chromosome 
17p11.2-q11.2 region coincides with the map coordinate for two potential 
candidate genes for fibromyalgia: the serotonin transporter gene 
(SLC6A4) and the transient receptor potential (TRP) vanilloid 2 (TRPV2) 
genes. 
FMS is multifactorial disorders and there is increasing evidence that it 
may be triggered by environmental factors and many authors have 
highlighted a relationship with various infectious agents and some have 
suggested that vaccinations may play a role (Cassisi G et al, 2011). There 
is no precise evidence of FMS due to infections or vaccinations and in 
particular, viruses such as HCV, HIV, and Parvovirus (Rivera J et al, 
1997; Leventhal LJ et al, 1991; Buskila D et al, 1990) could be involved.  
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1.1.4. Diagnosis 
Although fibromyalgia is the most common chronic widespread pain 
condition, it is often under diagnosed and recognition of FMS may not 
always be straightforward, because FMS symptoms may be part of- or 
overlap with - other diseases or syndromes. Furthermore the laboratory 
tests are limited to a complete blood count, erythrocyte sedimentation rate, 
rheumatoid factor, antinuclear antibody, thyroid-stimulating hormone, T3, 
T4, creatinine phosphokinase, serum muscle enzymes, vitamin D, C-
reactive protein (CRP) and typically there are no abnormalities 
specifically associated with this condition. As such, diagnosis is 
principally based on the two criteria defined by the American College of 
Rheumatology, (ACR) 1990 (Wolfe F et al, 1990): 1) a history of 
widespread pain that has been present for at least three months, and 2) 
Pain in 11 of 18 tender point sites on digital palpation (both side of the 
body): Occiput (2), Low cervical (2), Trapezius (2), Supraspinatus (2), 
Second rib (2), Lateral epicondyle (2), Gluteal (2), Greater trochanter (2), 
Knee (2) (Figure 1). 
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Figure 1. The black dots indicate the 18 tenderness points. 
The tender points are specific places on the body that are painful when a 
standard amount of pressure (about 4 Kg) is applied. Although not 
essential for diagnosis, sleep disturbance, fatigue and morning stiffness are 
present in the vast majority of patients; other quite common symptoms 
include cognitive problems, paresthesias, headache, irritable bowel or 
bladder and anxiety. Recently the ACR published modified preliminary 
diagnostic criteria which enable diagnosis without the tender point 
examination and includes the severity of fatigue, waking unrefreshed and 
cognitive symptoms as core diagnostic assessments. Two factors best 
discriminate between patients with FMS and those with other disorders: 
the Widespread Pain Index (WPI) and the Symptom Severity (SS) score 
(Wolfe F et al, 2010). The WPI is a count of number of painful body 
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regions and patients (or their physician) may endorse 19 body regions in 
which pain has been experienced during the past week and one point is 
given for each area, so the score is between 0-19. The SS score is a 
measure of cognitive symptoms, sleep, fatigue, and additional somatic 
symptoms (such as headache, weakness, bowel problems, nausea, 
dizziness, numbness/tingling, hair loss) and the patient ranks specific 
symptoms on a scale of 0-3. However, Toda K (2011) suggested that SS 
scale introduces ambiguity into the clinical diagnosis and this issue has 
begun be addressed in the modification of the 2010 ACR criteria. In their 
modified 2010 diagnostic criteria Wolfe et al retain the 19-site WPI and 
the self-reported specific symptoms, but eliminate the physician 
estimation of SS score and replace it with three dichotomous “yes/no” 
answers regarding the presence of abdominal pain, depression, and 
headaches in the past 6 months (Wolfe F et al, 2011). 
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1.1.4.1. Fibromyalgia Impact Questionnaire (FIQ) 
The Fibromyalgia Impact Questionnaire (FIQ) was developed by members 
of the fibromyalgia treatment team at Oregon Health & Sciences 
University (OHSU) in an effort to capture this total spectrum of 
fibromyalgia related symptoms (Burckhardt CS et al, 1991). This 
instrument measures physical functioning, work status (missed days of 
work and job difficulty), depression, anxiety, morning tiredness, pain, 
stiffness, fatigue, and well-being over the past week. The original FIQ 
contained 10 items (10 sub-items in the physical scale and consisted of 10 
items with 10 sub-items in the physical function scale (total items + sub-
items = 19). The original questionnaire used a visual analog scale (VAS) 
that required patients to slash a 100 mm line and was scored with a ruler. 
The scoring was further complicated by the need to reverse scores in one 
questions and the use of constants to convert the first 13 questions to a 
standardized scale of 0 to 10. Moreover, questions that now are considered 
relevant, such dyscognition (memory, executive function, concentration 
and attention; Ambrose KR et al, 2012), tenderness, balance, and 
environment sensitivity, were not part of the original FIQ. Modifications 
were made in 1997, 2002, and 2009, each with different scoring 
mechanisms. The 1997 modifications were the additions of an item to the 
physical function scale about stair climbing, hash marks to the visual 
analog scales, and the words "including housework" to the two work-
related items and consists of 20 items with 11 physical function items 
(total items + sub-items = 30). The scoring was modified in 2002 for FIQs 
that contained crossed-out questions or other incomplete data (Bennett 
RM et al, 2005). The final score was to be adjusted to reflect a final 
maximum score of 100 to maintain homogeneity on a 0 to 100 continuum, 
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both within and between studies. The FIQR  (Revised Fibromyalgia 
Impact Questionnaire) published in 2009 has the same 3 domains as the 
FIQ (i.e. Function, Overall Impact, and Symptoms) and consists of 21 
items across the 3 domains of Function (n = 9), Overall Impact (n = 2), 
and Symptoms (n = 10) (Bennett MR et al, 2009). It differs from the FIQ 
in having modified function questions and the inclusion of questions on 
memory, tenderness, balance, and environmental sensitivity. It has 
comparable scoring characteristics to the original FIQ, making it possible 
to compare past FIQ results with future FIQR results. The FIQ has been 
translated into several 14 languages (Appendix: Italian FIQ). 
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1.1.5. Treatment 
Since there is no definitive cure for FMS, treatment focuses on managing 
symptoms and improving overall quality of life. The aim of treating FMS 
is to decrease pain and increase function by means of a multimodal 
therapeutic strategy which, in most cases, includes pharmacological and 
non-pharmacologic interventions (Burckhardt CS et al, 2006) and has the 
main goal in symptom management (Barkhuizen A et al, 2002).  
The European League Against Rheumatism (EULAR) suggested 
guidelines for treatment in FMS (Carville SF et al, 2008). The most 
efficacious treatment of FMS requires a multidisciplinary approach 
combining pharmacological treatment, exercise and cognitive behavioral 
therapy (Sarzi-Puttini P et al, 2011). Both pharmacological and non-
pharmacological treatments have been shown to have an effect on 
symptom severity and physical function. The treatments need to be 
tailored with consideration to pain, fatigue, function and other features 
associated with FMS (Busch AJ et al, 2007; Carville SF et al, 2008; 
Mannerkorpi K et al, 2007).  
A pharmacological therapy is often necessary to mitigate the symptoms of 
fibromyalgia, particularly as symptom profiles vary between patients. 
Such a combination may involve antidepressants, non-steroidal anti-
inflammatory drugs (NSAIDs), sedatives, muscle relaxants, analgesics, 
sedatives, anticonvulsants, sleep aids and corticosteroids, depending on 
each patient’s clinical history, target symptoms and functional 
impairments (Han C et al, 2011; Moldofsky H et al, 2010; Russell IJ et al, 
2009; Di Franco M et al, 2010). In addition, adjunctive therapies may be 
prescribed to treat specific symptom domains such as sleep, and co-
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morbid conditions the patient may have, such as irritable bowel syndrome 
and rheumatoid arthritis (Mease PJ et al, 2011). 
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1.2. Proteomics 
The term ‘proteomics’ was first coined in 1995, and was defined as the 
large-scale characterization of the entire set of proteins expressed by a 
given cell, tissue, or organism. At present, proteomics is defined as large 
scale studies of the proteomes that encompass protein expression, folding, 
and localization. 
The protein expression analysis in body fluid, tissue and cells of different 
origin is became one of the main focus after completion of the human 
genome sequence (International Human Genome Sequencing Consortium, 
2004; Lander ES et al, 2001; Venter JC et al, 2001). 
There are several reasons for focusing on the analysis of proteins: the level 
of mRNA expression frequently does not represent the amount of active 
protein in a cell (Anderson L et al, 1997); the gene sequence does not 
describe post-translational modifications, which may be essential for 
protein function and activity; and the study of the genome does not 
describe dynamic cellular processes (Humphrey-Smith I et al, 1997). 
Many types of information cannot be obtained only from the study of 
gene, for example, proteins, not genes, are responsible for the phenotypes 
of cells. It is impossible to elucidate mechanism of disease, aging, effects 
of the environment solely by studying the genome.  
Currently, 4543 genomes are being sequenced in ongoing projects, of 
which 3271 are bacterial, 110 archaeal and 1162 are eukaryotic (Liolios K 
et al, 2010). The available genome sequences provide useful information 
to the proteomics. From the DNA sequence it is possible to theoretically 
say what proteins may be present in a sample. Furthermore, a known gene 
sequence is commonly used to identify and verify proteins detected by 
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various proteomics methods. Actually, a significant portion of all 
sequenced genomes today encodes proteins remaining to be characterized. 
While the set of genes in a cell, its genome, is essentially static over time, 
the composition and levels of mRNAs and expressed proteins is 
fluctuating as the cell adapts to environmental and life cycle situations at 
every single time point. 
If a gene or protein is shown to be involved in a pathway or mechanism 
responsible for a diseased cell fate, it may be a good target for diagnosis, 
treatment or even prevention of that fate. 
Proteomes of higher eukaryotes are very complex and several properties 
make the proteomic exploration enormously demanding. For instance, a 
factor to deal with in proteomics is the huge dynamic range in relative 
abundance of different proteins in a biological sample (Anderson NL et al, 
2002). 
This makes complicated detect rare protein species without extensive 
preparatory work as fractionation or depletion of several abundant protein 
species. Other critical factors are, alternative promoter usage and a number 
of post-transcriptional alterations of proteins including, alternative splicing 
and post-translational modifications (PTMs) (Godovac-Zimmermann J et 
al, 2005). Proteomics is supremely well suited to the analysis of human 
body fluids. Proteins in these fluids are typically soluble in nature, making 
them highly suitable to analysis using a variety of proteomics techniques. 
Whereas body fluids are well suited to analysis using proteomics, the 
application of m-RNA-based techniques such as polymerase chain 
reaction or hybridization array is largely irrelevant for the study of such 
fluids. This is because the cells that produce proteins in body fluids are 
either not found in the fluids (e.g. urine) or are some distance away from 
where the fluids are usually sampled (e.g., cerebrospinal fluid). 
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Additionally, proteins in some body fluids (e.g. serum or plasma) originate 
from cells that are present in multiple tissues. For these reasons, there is 
enormous interest in the use of proteomics for the study of human body 
fluids, in an attempt to understand better the normal physiology and 
pathophysiology of disease and to discover biomarkers. A number of 
proteomic technologies are commonly used for analysis of human body 
fluids. Typically, these technologies combine one or more means of high-
resolution protein separation with high-sensitivity detection techniques. 
There are numerous techniques used to separate proteins derived from a 
tissue or biological fluid, but the current state of art is the 2-D Gel 
Electrophoresis (2-DE) followed by staining and mass spectrometric 
identification of protein spots. 2-DE not only generates information 
regarding protein modification and/or expression level changes, but also 
allows for the isolation of proteins in milligram amounts for further 
structural analyses, using mass spectrometry. The quantitative analysis of 
the images generated by digitization of 2D gels is critical for the 
identification of alterations in protein expression within a given biological 
system. 
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1.2.1. Proteomics of serum for biomarker identification  
One of the important goals of biomedical research is to identify 
biomarkers that reflect an individual’s health or disease state. Biomarkers 
of disease can be used for early diagnosis, therapeutic monitoring, and 
detecting the relapse of disease (Adkins JN et al, 2002; Verrills NM, 
2006).  
Blood is the most common source of biomarkers for use in the diagnosis 
and prognosis of disease (Anderson NL, et al, 2002). Blood constantly 
perfuse most tissues of the human body and the serum carries not only 
blood-specific proteins but also proteins that are synthesized, secreted, or 
shed from cell throughout the body (Anderson NL et al, 2004). Since 
serum is readily accessible, biomarkers that are identified in serum can 
serve as diagnostic tests and as targets for therapeutic intervention. The 
application of proteomic techniques to human serum may also have 
particular relevance to inflammatory vascular conditions such as systemic 
vasculitis, a group of disorders in which the site of pathology – the blood 
vessel wall – is in direct contact with the serum. The ability to make 
accurate inferences about the state of pathology (or health) within organ 
systems by examining the fluid that perfuse them has several major 
potential advantages. First, because traces of the molecular footprints of 
disease are expected to equilibrate (even at minute quantities) in the 
serum. Second, findings in the serum represent the sum of disease 
processes in organs, even those in which clinical involvement is 
unrecognized.  
In addition, serum may be advantageous in searches for new peptide and 
protein markers, because the proteins and peptides that persist after blood 
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clotting are sufficiently stable to be exploited for in vitro diagnostics (Rai 
AJ et al, 2006).  
Recently, the discovery of biomarkers from blood (serum or plasma) has 
become the subject of intensive attention, and the analysis of large 
numbers of proteins via proteomic techniques has greatly accelerated our 
ability to identify new biomarkers for disease including cancer (Li J et al, 
2005), diabetes (Allard L et al, 2005), stroke (Zimmermann-Ivol CG et al, 
2004) and kidney diseases (Merchant ML et al, 2005). As plasma contains 
such a variety of proteins in a wide and dynamic concentration range, two-
dimensional gel electrophoresis (2-DE) and mass spectrometry (MS) are 
currently the principal techniques for the separation of such complex 
protein mixtures (O’Farrell PH et al, 1975;. Anderson L et al, 1977; 
Cristea IM et al, 2004).  
Owing to these advantages, 2-DE has been used extensively for the 
discovery of new biomarkers (Jacobs JM et al, 2005; Nedelkov D et al, 
2005; Thadikkaran L et al 2005). Examples of biomarkers identified via 2-
DE are provided in Table 2 (Kim MR et al, 2007). 
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Context Biomarker(s) Identified 
Benzen exposure T cell receptor β-chain, FK506-binding protein, matrix 
metalloproteinase-13 
Polycyclic hydrocarbon exposure Putative capacitative calcium entry channel 
Strock Fatty acid binding protein (FABP) 
Ovarian cancer Haptoglobin-α 
Gastric carcinoma Annexin V, carbonic anhydrase, prohibitin, fibrin beta, 
fibrinogen fragment D 
Cardiovascular Mature Cathepsin D 
Severe acute respiratory syndrome Peroxiredoxin II 
Severe acute respiratory syndrome Truncated  α1-antitrypsin 
Lung cancer Haptoglobin, HGF 
Pregnancy Clusterin 
Acute myeloid leukemia   
  
α -2-HS glycoprotein, complement-associated SP-40, 
RBP4, lipoprotein C-III, haptoglobin, immunoglobulin 
heavy-chain variant, proteosome 26S ATPase subunit 1, 
haptoglobin-1 
Myocardial infarction Antitrypsin isoform 1 
Cardiac allograft rejection α Crystallin, tropomyosin 
Relapsing polychondritis Tubulin α ubiquitous, vimentin, alpha enolase, calreticulin, 
colligin-1 
Table 2. Examples of biomarkers identified by 2-DE 
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1.2.2. Techniques in proteomics 
Ever since its introduction in the mid-1970s, two-dimensional sodium 
dodecylsulfate polyacrylamide gel electrophoresis (2D SDS-PAGE) has 
been a workhorse for separation of proteins in complex mixtures (Klose J 
et al, 1975; O’Farrell, 1975). 
The technique separates proteins both in terms of their isoelectric points 
(pI) and molecular weights (Mr), and it is essentially a stepwise separation 
tool that combines isoelectric focusing and SDS-PAGE. 
Using the current 2D PAGE technologies it is possible to separate 
complex protein mixtures into their individual polypeptide components 
and compare the protein expression profiles of sample pairs (normal 
versus transformed cells, cells at different stages of growth or 
differentiation, etc).  
Furthermore, it delivers a map of intact proteins, which reflects changes in 
protein expression level, isoforms or post-translational modifications. 
Protein profiles can be scanned and quantitated to search for protein 
differences and interesting targets or molecular signatures can be 
identified using additional proteomic technologies such as mass 
spectrometry and Western blotting. 
In combination with MALDI-TOF MS, 2D-PAGE constitutes the standard 
method in expression proteomics. Prior to MS-analysis, the proteins are 
enzymatically digested in the gel and thereafter extracted into liquid 
phase. The masses of the resulting peptides are determined by MS. As the 
genomes of many organisms are known, theoretical masses of translated 
proteins can be calculated. Bioinformatics tools, e.g. Mascot 
(www.matrixscience.com) and ProFound 
(http://prowl.rockefeller.edu/prowl-cgi/profound.exe), are used to match 
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the measured masses to theoretical masses from protein databases, and to 
estimate the probability that the ‘‘peptide mass fingerprint’’ originates 
from a certain protein. 2D-PAGE is a robust method that separates intact 
proteins, and reflects the presence of isoforms, post-translational 
modifications and the expression levels. At present, 2D-PAGE can resolve 
more than 5000 protein simultaneously (2000 proteins routinely) and can 
detect <1 ng protein per spot (Görg A et al, 2004). However, it is difficult 
to discriminate the proteins of extreme size and very hydrophobic, and 
also the method is rather labor intensive, difficult to automate and time 
consuming.  
The major steps of the 2-D electrophoresis –MS workflow include: (i) 
Sample preparation and protein solubilization; (ii) Protein separation 2-D 
PAGE; (iii) Protein detection and quantitation; (iv) Computer assisted 
analysis of 2-D patterns; (v) Protein identifications and characterizations 
(Figure 2). 
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Figure 2. Classical proteomics approaches (2-DE followed by MS). 
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1.2.2.1. Two-dimensional Polyacrylamide Gel Electrophoresis 
This technique combines isoelectric focusing, as a first dimension of 
separation, and sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) as a second dimension.  
 
1.2.2.2. Isoelectric Focusing  
To take advantage of the high resolution of 2-DE, proteins of the sample 
have to be denaturated, disaggregated, reduced and solubilized to achieve 
complete disruption of molecular interactions and to ensure that each spot 
represent an individual polypeptide. 
The isoelectric focusing first involves the extraction and solubilization of 
proteins using a buffer containing a variety of solubilizing agents such as: 
 Urea or Thiourea: detergents; the high concentration is needed to 
convert proteins into single conformation by cancelling the 
secondary and tertiary structures, to get and keep hydrophobic 
proteins in solution, and to avoid protein-protein interaction. 
Recently, the use of thiourea in addition to urea has been found to 
further improve solubilization, particularly of membrane proteins. 
 3-[(3-Cholamidopropyl)dimethylammonio]-2-hydroxy-1-
propanesulfonate (CHAPS): a zwitterionic detergent increases the 
solubility of hydrophobic proteins 
 Dithiothreitol (DTT): reductant, prevent different oxidation steps of 
the proteins. 
 Carrier ampholytes: which had been designed for generating pH 
gradient, improve the solubility of proteins considerably by 
substituting ionic buffers. 
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Isoelectric Focusing (IEF) is an electrophoretic method that separates 
proteins according to their isoelectric points (pI). The first-dimension IEF 
depended on carrier-ampholyte-generated pH gradients, Görg A et al. 
(1988; 2000) pioneered the development and use of immobilized pH 
gradients (IPG) IEF for the first-dimension of 2-D electrophoresis. An 
immobilized pH gradient is created by covalently incorporating a gradient 
of acidic and basic buffering groups (Immobilines) into a polyacrylamide 
gel at the time it is cast. Immobiline buffers are a set of well-characterized 
molecules, each with a single acidic or basic buffering group linked to an 
acrylamide monomer. 
The general structure of Immobiline reagents is: 
                              CH2     CH–C    NH–R 
                     O 
R = weakly acidic or basic buffering group 
After IEF, the Immobiline DryStrip gels are equilibrated in equilibration 
solution and applied onto vertical or flatbed SDS-polyacrylamide gels for 
the second-dimension separation. The equilibration solution contains 
buffer, urea, glycerol, reductant, SDS, and dye. An additional equilibration 
step replaces the reducing agent with iodoacetamide. 
Equilibration buffer (75 mM Tris-HCl, pH 8.8) maintains the Immobiline 
DryStrip gel in a pH range appropriate for electrophoresis. 
Urea together with glycerol reduces the effects of electroendosmosis by 
increasing the viscosity of the buffer. 
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Glycerol (30%) together with urea reduces electroendosmosis and 
improves transfer of proteins from the first to the second dimension. 
Dithiothreitol (DTT) preserves the fully reduced state of denatured, 
unalkylated proteins. 
Sodium dodecyl sulfate (SDS) denatures proteins and forms negatively 
charged protein-SDS complexes. 
Iodoacetamide alkylates thiol groups on proteins, preventing their 
reoxidation during electrophoresis.  
Tracking dye (bromophenol blue) allows monitoring of the progress of 
electrophoresis. 
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1.2.2.3. Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
SDS-PAGE is an electrophoretic method for separating polypeptides 
according to their molecular weights. The technique is performed in 
polyacrylamide gels containing sodium dodecyl sulfate (SDS). SDS masks 
the charge of the proteins themselves and the formed anionic complexes 
have a roughly constant net negative charge per unit mass. Besides SDS, a 
reducing agent such as DTT is also added to break any disulfide bonds 
present in the proteins. When proteins are treated with both SDS and a 
reducing agent, the degree of electrophoretic separation within a 
polyacrylamide gel depends largely on the molecular weight of the 
protein. The effective molecular weight range for proteins on SDS-PAGE 
can be tailored by adjusting the pore size of the gel. This is done by 
changing the concentration of acrylamide and cross-linking bis-acrylamide 
prior to polymerization. Typical concentrations are 12.5% T with 3% C 
for most SDS-PAGE separations with effective molecular weight 
separation between 14 and 100 kDa. The pH of the resolving gel is about 
8.8, while the pH of the stacking gel is a lower at 6.8, buffered using Tris-
HCl. The most commonly used buffer system for second-dimension SDS-
PAGE is the Tris-Glycine system described by Laemmli UK, (1970). This 
buffer system separates proteins at high pH, which confers the advantage 
of minimal protein aggregation and clean separation even at relatively 
heavy protein loads.  
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1.2.2.4. In-gel Visualization 
Following separation using 2D PAGE, proteins are visualized through 
staining techniques: Silver staining (Shevchenko A et al, 1996), 
Coomassie staining (Neuhoff V et al, 1988), fluorescent (Lopez MF et al, 
2000; Berggren K et al, 2000) and autoradiography (Patton WF et al, 
2002). Of these, silver staining is the most common used technique, as it 
detects as small a quantity as a single nanogram but its dynamic range is 
also restricted to a single order magnitude scale. Coomassie staining is an 
easy to use, low- cost staining agent, but a small linear dynamic range. 
Finally, despite of its high cost, fluorescent detection is gaining in 
popularity because of its sensitivity and wider linear dynamic range 
(Patton WF et al, 2002). Other methods for improving gel staining include 
differential gel electrophoresis (DIGE) (Unlu M et al, 1997), which 
substantially reduces variability by displaying two or more complex 
protein mixtures labeled with different fluorescent dyes in a single 2D gel. 
Fluorescent labeling also renders 2-D DIGE much more quantitative than 
colorimetric methods. It has a linear dynamic range of four or five orders 
of magnitude, by contrast with the approximately one- or two- order range 
of colloidal Coomassie or Silver stains (Tonge R et al, 2001). After protein 
separation and staining, further computer-based analysis is needed to 
detect differentially expression proteins. Computer programs are 
continuously being developed and improved - eg Progenesis (Nonlinear 
Dynamic), Image Master 2D Platinum and Melanie Software (GE 
Healthcare) or PDQuest (Biorad) - but image analysis remains a time-
consuming process. Protein identification is based on matching peptide 
experimental masses of digested protein (PMF), using MS or tandem mass 
spectrometry (MS/MS) (Corthals, GL et al, 1999), versus the theoretical 
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masses obtained in the in silico digestion of all protein in a specific 
database. The result is a list of candidate proteins with different 
confidence levels.  
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1.2.2.5. Mass Spectrometry  
Current mass spectrometers can detect and identify peptides in the 
femtomole (10
−15
) to attomole (10
−18
) range (Moyer SC et al, 2003). There 
are many types of mass spectrometers that can be used for proteomic 
studies, and each accomplishes the task of peptide identification in a 
slightly different way. All mass spectrometers consist of three basic 
components: ion source, mass analyser and ion detector. The role of the 
ion source is to introduce molecules into the mass spectrometer and 
convert them to a charged or ionized from. The ion source like the rest of 
the mass spectrometer is usually, though not always, held at a low 
pressure. Mass spectrometers are operated under vacuum to prevent the 
collision of ions with residual gas molecules during their flight from the 
ion source to the detector. This is because the ion are formed with excess 
energy and this, together with their charged character, can result in their 
reaction with other gaseous material present. The ideal operating pressure 
is that in which the average distance an ion travels before colliding with a 
gas molecule is longer than the distance from the source to the detector. 
After ions are formed in the source, they are accelerated into the mass 
analyser where they are separated in vacuum according to their mass and 
charge through the use of electric and/or magnetic field. Finally, the ions 
are passed onto an ion detector producing an electrical current that is 
amplified and detected (Figure 3). 
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Figure 3. Schematics of a simple mass spectrometer with source, analyser and ion 
detector. 
In the last twenty years, thanks to the development of soft ionization 
technique like Electrospray Ionization (ESI) and Matrix-Assisted Laser 
Desorption Ionization (MALDI), mass spectrometry found a considerable 
employment in the study of proteins. After initial protein digestion 
typically with trypsin, the obtained peptides are ionized in the ion source 
of the mass spectrometer. Peptides are then detected by the analyser of the 
mass spectrometer and in some cases they can be isolated and fragmented 
in order to obtain information on their aminoacidic sequence. Ionization of 
peptides is the first step in mass spectrometry of proteomes. The most 
frequently used ionization methods is matrix-assisted laser desorption 
ionization (MALDI; Yates, 1998) that is soft ionization technique. In 
MALDI, the analyte of interest is mixed with a large mole excess of (ca. 
1,000-fold) a matrix compound that absorbs efficiently at the laser 
wavelength. The matrix allows the energy from laser to be dissipated and 
also assists with the ionization sample molecules through electron transfer 
and chemical processes. Common MALDI matrices are 2,5-
dihydroxybenzoic acid (2,5-DHB), 2,4,6-trihydroxyacetophenone 
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(THAP), α-cyano-4-hydroxycinnamic acid (CHCA), sinapinic acid (SA) 
and 2,4-dihydroxyacetophenone (DHAP) (Figure 4). Where a UV laser is 
used MALDI matrices include sinapinic acid (SA) for proteins and α-
cyano-4-hydroxycinnamic acid (CHCA) for peptides. 
 
 
Figure 4. Structural formulas of used MALDI matrices: (A) 2,5-dihydroxybenzoic 
acid (2,5-DHB), (B) 2,4,6-trihydroxyacetophenone (THAP), (C) α-cyano-4-
hydroxycinnamic acid (CHCA), (D) sinapinic acid (SA) and (E) 2,4-
dihydroxyacetophenone (DHAP). 
MALDI is now a firmly established technique, particularly for the study of 
polar, high molecular weight compounds such as proteins, 
glycoconjugates and nucleic acid. The peptide’s mass is typically 
expressed as the mass to charge ratio (m/z). MALDI allows the 
protonation of analyte. The same peptide population may gain a different 
number of protons. The analyser is the part of the mass spectrometer 
where electric and/or magnetic fields are used for separating ions in gas 
phase. Mass spectrometer may be constructed with one or more analysers, 
depending on the task they will be used for. Instruments composed of two 
or more mass analysers coupled together are known as tandem mass 
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spectrometers. Until the spurt in interest in proteomics during the 1990s 
analyser like time-of-flight (TOF) (Figure 5) and the particularities and 
usefulness of the most used tandem TOF (TOF/TOF). The TOF is the 
simplest mass analyser and it consists essentially of a flight tube in high 
vacuum. Ions, accelerated with equal energies, fly along the tube with 
different velocities, which are inversely proportional to their mass. 
 
Figure 5. Schematic layout of a MALDI-TOF instrument 
The time-of-flight (TOF) mass spectrometers separate ions and measure 
their m/z based on the time they take to pass (‘fly’) from the ion source to 
detector. The flight tube is usually 1-2 m in length and the basis of the 
separation makes no use of either electric or magnetic fields. Ions are 
separated in the field-free region of the flight tube before reaching the 
detector. The TOF spectrum is a recording of the signal produced by an 
ion detector at the end of the flight tube upon the impact of each ion 
group. A conventional mass spectrum, displaying intensity over m/z ratio 
is achieved by taking into account the relationship of the time of arrival to 
the detector (t) with the square root of m/z ratio value of the ion. The 
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coupling of a MALDI source with instruments capable of an efficient 
peptide isolation and fragmentation has proved to be very useful. When a 
protein cannot be identified by peptide mass fingerprinting (PMF), it 
would be very interesting to obtain peptide fragmentation data using the 
same sample without further purification. In this way, ambiguous PMF 
matches could be transformed into significant hits when enriched with the 
fragmentation data from at least one peptide. TOF/TOF has been coupled 
to MALDI sources and constitutes today workhorses for high throughput 
proteomics (Baldwin MA et al, 2001). The interpretation of the resulting 
MS/MS spectrum allows for the sequencing of the peptide. Each spectrum 
must be analyzed and a sequence of the peptide determined. Various 
software has been developed to either de novo sequence or match the 
spectra to known peptides. These peptides sequences are associated to 
proteins, and the proteins are identified with variable confidences based on 
the number and quality of the peptides sequenced. Most of the protein 
identification software (e.g. MASCOT, Seaquest) starts with the 
assumption that the peptide is being sequenced is in the protein database. 
If this assumption is not true, these programs will find the best matching 
peptide in the database and in the case of highly homologous proteins, 
sufficient identity may exist to correctly sequence a peptide and make a 
protein match in another closely related species. In addition, these protein 
sequencing software packages allow for several mismatches between the 
mass spectrometry data and the database; this allows identification of 
closely related proteins but can affect the confidence scoring of the 
protein. Thus, the quantity and quality of protein identification is affected 
by the quality of the protein databases. 
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1.2.3. Proteomics in fibromyalgia  
In the last few years the proteomic approach has been widely used in order 
to identify new diagnostic biomarkers and therapeutical targets for a 
plethora of diseases, including FMS. Recently Giacomelli C et al, (2011) 
identify potential salivary FMS biomarker through a salivary proteomic 
tandem analysis based on MALDI-TOF and SELDI-TOF techniques. The 
peaks observed were likely to belong to the calgranulin family, and they 
are involved in cellular proliferation and migration, calcium homeostasis, 
inﬂammation and cellular protection against oxidative stress. Another 
peak observed with both techniques corresponded to the protein called 
Rho GDP-dissociation inhibitor2. This protein is involved in the 
RhoGTPasi activity, which controls cellular morphology and motility. 
Thus the peaks observed allow the research to focus on some of the 
particular pathogenic aspects of FMS: the oxidative stress, which 
contradistinguishes this condition, the involvement of proteins related to 
the cytoskeleton arrangements, and ﬁnally the central sensitization.  
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1.3. Purine 
Purine metabolism involves synthesis and degradation of purine 
nucleotides and determines adenylate and guanylate pool values; 
consequently it is responsible for intracellular adenosine-5'-triphosphate 
(ATP) and guanosine-5'-triphosphate (GTP) concentrations. In addition to 
their roles within cells, purine nucleotides, nucleosides and bases and their 
metabolic products are released into the extracellular space where they act 
as signaling molecules. Receptor subtypes for purines have been identified 
in a variety of tissues, increasing interest in the role of purine-mediated 
signaling in pathophysiological processes and in the role of purine 
nucleotides and nucleosides in pain pathways (Burnstock G, 2006). 
Prompt effects are mediated by purines in the nervous system some of 
which are consequent to binding to purinergic surface receptors whereas 
others require purine uptake by cells. Extracellular purine concentrations 
depend on several factors which include the amount of purines released, 
local extracellular volume, uptake mechanisms and the presence of 
extracellular enzymes which metabolize purines. Once released, purine 
nucleotides and nucleosides undergo a complex extracellular metabolism 
catalyzed by many cell surface-located enzymes. Moreover, Yegutkin and 
co-workers (2003) revealed the existence in human serum of soluble 
enzymes capable of both inactivating and transphosphorylating circulating 
purines. Purine nucleosides, such as adenosine and its primary metabolite 
inosine, are low-molecular-weight molecules that participate in a wide 
variety of intracellular biochemical processes. Although both adenosine 
and inosine are present at low levels in the extracellular space, 
metabolically stressful conditions lead to an increase in their extracellular 
concentrations. Inosine is formed from adenosine both intracellularly and 
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extracellularly; inosine monophosphate (IMP) is dephosphorylated to 
inosine inside the cell and when inosine reaches high intracellular 
concentrations, it is shunted into the extracellular space by bidirectional 
equilibrative nucleoside transporters (Haskó G, 2004); inosine is degraded 
to hypoxanthine and then xanthine.  
Inflammation, hypoxia and tissue injury cause adenosine degradation and 
the generation of its metabolite inosine (Eltzschig HK, 2009), a process 
mediated by adenosine deaminase (Spicuzza L et al 2006; Trams EG et al, 
1974). 
Some purine nucleotide metabolism disorders such as myoadenylate 
deaminase (MAD) deficiency report symptoms similar to those seen in 
FMS; the spectrum of symptoms of MAD deficiency ranges from 
permanent muscular hypotonia to excessive muscle weakness, fatigue, 
soreness, stiffness or cramps, and pain after exercise (Zöllner N et al, 
1986) and these symptoms are consequences of an interruption of the 
purine nucleotide cycle. 
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1.4. High performance liquid chromatographic (HPLC) 
High-performance liquid chromatography (HPLC) is a versatile analytical 
technology widely used for the analysis of pharmaceuticals, biomolecules, 
polymers, and many organic and ionic compounds. The first generation of 
high-performance liquid chromatographs was developed by researchers in 
the 1960s, including Horvath, Kirkland, and Huber. HPLC is a modern 
form of Liquid chromatography (LC) that uses small-particle columns 
through which the mobile phase is pumped at high pressure.  The principle 
of LC is a separation process based on distribution between two phases, 
where the sample components is propelled by liquid which percolates a 
solid stationary phase. A sample is separated into its constituent 
components (or analytes) by distributing between the mobile phase (a 
flowing liquid) and a stationary phase (sorbents packed inside a column). 
A variety of liquids and stationary phases can be used in liquid 
chromatographic systems. HPLC is accomplished by injection of a small 
amount of liquid sample into a moving stream of liquid (called the mobile 
phase) that passes through a column packed with particles of stationary 
phase. Separation of a mixture into its components depends on different 
degrees of retention of each component in the column. The extent to 
which a component is retained in the column is determined by its 
partitioning between the liquid mobile phase and the stationary phase. In 
HPLC this partitioning is affected by the relative solute/stationary phase 
and solute/mobile phase interactions. Since the compounds have different 
mobilities, they exit the column at different times; i.e., they have different 
retention times, tR. The retention time is the time between injection and 
detection.  
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There are numerous detectors which can be used in liquid 
chromatography. It is a device that senses the presence of components 
different from the liquid mobile phase and converts that information to an 
electrical signal (Figure 6).  
 
 
Figure 6. Schematic of an HPLC system. A high-pressure pump delivers a constant 
stream of mobile phase to the HPLC column. A plug of the sample to be analyzed is 
injected into this stream. At the outlet of the column, the separated components of 
the sample are detected and appear as peaks on the chromatogram. 
For qualitative identification one must rely on matching retention times of 
known compounds with the retention times of components in the unknown 
mixture. Thus HPLC is most often used when one is performing a target 
compound analysis, where one has a good idea of the compounds present 
in a mixture so reference standards can be used for determining retention 
times. Today, HPLC continues to evolve rapidly toward higher speed, 
efficiency, and sensitivity, driven by the emerging needs of life sciences 
and pharmaceutical applications. HPLC is a premier separation technique 
capable of multicomponent analysis of real-life samples and complex 
mixtures. Few techniques can match its versatility and precision of <0.5% 
relative standard deviation (RSD). A host of highly sensitive and specific 
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detectors extend detection limits to nanogram, picogram, and even 
femtogram levels. As a preparative technique, it provides quantitative 
recovery of many labile components in milligram to kilogram quantities.  
In Reversed-Phase Chromatography (RPC) the separation is based on 
analytes’ partition coefficients between a polar mobile phase and a 
hydrophobic (nonpolar) stationary phase. The earliest stationary phases 
were solid particles coated with nonpolar liquids. These were quickly 
replaced by more permanently bonding hydrophobic groups, such as 
octadecyl (C18) bonded groups, on silica support. A simplified view of 
RPC is shown in Figure, where polar analytes elute first while nonpolar 
analytes interact more strongly with the hydrophobic C18 groups that form 
a “liquidlike” layer around the solid silica support. RPC typically uses a 
polar mobile phase such as a mixture of methanol or acetonitrile with 
water. The mechanism of separation is primarily attributed to solvophobic 
or hydrophobic interaction. It is suitable for the analysis of polar (water-
soluble), medium-polarity, and some nonpolar analytes. Ionic analytes can 
be separated using ion-suppression or ion-pairing techniques. Separation 
of a mixture into its components depends on different degrees of retention 
of each component in the column. 
Each purine bases its own characteristic UV absorbance spectrum which 
can be used for identification purpose. Single-wavelength UV detection in 
the HPLC analysis is usually set a 254 nm, where virtually all substance 
have an absorbance maximum.  
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2. AIMS OF THE STUDY 
Currently no validated biomarkers are available for FMS and the diagnosis 
of the disease remain exclusively clinical. The aim of this study was to 
find biomarkers to be used to identify individuals susceptible to the FMS 
and to obtain the targeted diagnosis of FMS. Also monitoring and clinical 
assessment might be improved by useful serum biomarker.  
We conducted experiments through the use of two different methods to 
identify potential biomarkers for FMS: 
1 2-DE in combination with MS to obtain the serum protein map of 
FMS patients and controls. 
2 RP-HPLC to determine levels of some purine metabolites in serum 
samples. 
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3. MATERIAL AND METHODS 
3.1. Human subjects 
Twenty-two females (53.5 ± 2.3 years; mean age ± S.D.) affected by FMS 
were studied for analysis of purine metabolite and sixteen females (52 ± 
12 years; mean age ± S.D.) for analyses of proteome  were enrolled; 
diagnosis was based on a history of widespread pain, deﬁned as bilateral, 
upper and lower body, as well as in the spine, and the presence of 
excessive tenderness on applying pressure to 11 of 18 speciﬁc muscle–
tendon sites (Tender Points) according to the ACR classiﬁcation criteria 
(Wolfe F et al, 1990). The presence of a major clinical condition other 
than ﬁbromyalgia was excluded by physical examination and routine 
blood and urine screening. All FMS patients were examined by a qualiﬁed 
rheumatologist and were interviewed by the examining physician using 
the Fibromyalgia Impact Questionnaire (FIQ; see Appendix) (Bennet R et 
al, 2005). Clinical monitoring included the 100 mm non anchored 
horizontal Visual Analogue Scale for pain (patient and medical VAS 
pain). Twenty-two healthy women (49.7 ± 2.3 years; mean age ± S.D.) 
were recruited as controls for analysis of purine metabolite and twelve 
controls for analyses of proteome (48 ± 13 years; mean age ± S.D.) were 
enrolled.  
The samples were provided by Department Medical Science "Mario 
Aresu", University Hospital of Cagliari and informed consent was 
obtained from all the individuals enrolled on the study. 
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3.2. Blood collection  
Blood sample were collected after overnight fasting. These were 
centrifuged (3000 rpm for 20 min) and serum were stored at -80°C until 
sample preparation. Only serum samples without hemolysis (proved by 
hemoglobin levels not detectable) were stored at -80°C until sample 
preparation. 
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3.3. Analysis of serum proteome 
3.3.1. Protein quantification by 2-D Quant Kit 
Serum protein concentrations were quantified using the PlusOne 2D Quant 
Kit (GE Healthcare, Uppsala, Sweden) according to manufacturer's 
instructions previously diluted 1:10 with rehydration solution (8 M Urea, 
4% CHAPS, 1%  dithiothreitol ( DTT), 15mM Tris, 2% 3-10 ampholytes). 
The 2-D Quant kit quantitatively precipitates protein, leaving the 
interfering substances in solution. It is based on the specific binding of 
copper ions to proteins. The precipitated proteins are resuspended in a 
copper containing solution of which the unbound copper is then measured 
with a colorimetric agent at 480 nm. The color density is inversely related 
to the protein concentration. In short, a standard curve containing 5 
dilution (0, 10, 20, 30, 40, 50 µg) was prepared using the 2 mg/ml BSA 
stock solution provided by kit (Graphic 1). Varying volumes of serum 
protein dilution (2, 4, 8 µl) were used to determine the protein 
concentration of each serum sample. 550µl precipitant were added to each 
tube and vortexed, followed by 500 µl of co-precipitant and mixed by 
inversion immediately upon addition. Samples were centrifuged at 10000 
x g for 5 min at 20°C. The supernatants were decanted and centrifuged for 
1 min at 10000 x g, 20°C. The remaining supernatant was removed, before 
the addition of 100 µl of copper containing solution followed by 400 µl 
MilliQ water and mixing each tube. This was followed by the addition of 
1ml working solution to each tube, which was mixed immediately upon 
addition to ensure rapid mixing, before proceeding to the next tube. The 
tubes were then incubated for 15 min at room temperature, before the 
absorbance was measured at 480 nm by spectrophotometric techniques 
(Cary 50, Varian). 
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Graphic 1. Standard curve for albumin 
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3.3.2. Two-dimensional gel electrophoresis (2-DE) 
3.3.2.1. Isoelectric focusing 
For 2-DE 350 μl of rehydration buffer was pipetted along the length of the 
strip holder, avoiding any formation of bubbles. The Immobilized PH 
Gradient (IPG) strip was put onto the strip holder before layering mineral 
oil over the top of the strip, just enough to cover the strip and were started 
passive rehydration at room temperature overnight. The day after, two 
hundred micrograms of protein in rehydration buffer (8 M Urea, 4% 
CHAPS, 1% DTT, 15mM Tris and 2% 3-10 ampholytes) was applied to a 
18 cm IPG, strip pH 3-10. First dimensional IEF was performed on an 
Multiphor II flatbed electrophoresis system (GE Healthcare) with a 
MultiTemp III thermostatic circulator (Amersham Biosciences) and an 
EPS 3501 XL power supply (GE Healthcare). Strips were focused using 
the protocol shown in Table 3 and was always allowed to proceed to a 
total of 55250 Volt-hours, that completed within 20 h at 20 °C. Strips were 
stored at −20 °C after focusing was completed. 
STEP VOLTAGE 
LIMIT (V) 
HOUR 
(h) 
VOLT 
HOUR (Vh) 
GRADIENT 
1 500V 0:01h 1Vh Step and holder
a
 
2 500V 3h 1500Vh Step and holder 
3 3500V 5h 10000Vh Gradient
b
 
4 3500V 12,5h 43750Vh Step and holder 
Total   55250Vh  
 
a 
Step and holder Vh = h x V 
b 
Gradient      
                                  
 
 
Table 3. The IEF steps used for strips 18 cm IPG, pH 3-10.  
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3.3.2.2. SDS PAGE 
Following IEF, After the IEF the strips were equilibrated for 15 min in a 
solution containing 1% (w/v) DTT, 6 M urea, 2% (w/v) SDS, 50 mM Tris-
HCl pH 8.8 and 30% (v/v) glycerol. A second equilibration step was 
carried out for 15 min in the same solution except for DTT, which was 
replaced by 2.5% (w/v) iodoacetamide and trace of bromophenol blue. 
Finally, the strip was placed in SDS electrophoresis running buffer (0.25 
M Tris-HCl pH 8.3, 0.1% SDS, 192 mM glycine) for 2 min as a final 
equilibration step. Second dimensional separation was performed by 
placing the IPG strips on top of the 10% SDS PAGE gel (Ettan Daltsix, 
GE Healthcare), covered with 0.5% agarose dissolved in 1% SDS 
electrophoresis running buffer. Separation was performed at 25°C until the 
bromophenol blue front reached the bottom of the gel. Steps is given in 
table 4 .  
 
Step mA/gel Voltage (V) W/gel Time (h:min) 
1 10 80 1 1:00 
2 40 500 13 4:30-6:00 
a
 
a  continue the electrophoresis until the bromophenol blue reaches the end of the gel 
Table 4. Running condition using Ettan Daltsix electrophoresis system. 
 
The gels were then fixed in the appropriate fixing solution for each 
specific stain. 
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3.3.3. Staining of 2-DE gels 
3.3.3.1. Silver staining 
After electrophoresis, gels were fixed in 40% ethanol, 10% acetic acid 
overnight, followed by sensitizing for 1h in sodium thiosulfate (2 g/L), 
sodium acetate (68 g/L), 30% ethanol, and rising with Milli-Q water cold 
forth. 0.2% silver nitrate, 0.04% formaldehyde was added and incubated 
for 1 h in dark, rinsed twice with Milli-Q water and develop in 2% sodium 
carbonate with 0.04% formaldehyde. The solution is prepared just before 
use. Development was stopped by adding 1% EDTA. All gels were stored 
in airtight containers. 
 
3.3.3.2. Colloidal Coomassie Brillant Blue G-250 stain  
After electrophoresis, gels were fixed in 30% ethanol, 2% phosphoric acid 
overnight, followed by 2% phosphoric acid for ten minutes for three time. 
Colloidal Coomassie Brillant Blue G250 stock solution (10% ammonium 
sulphate, 1% phosphoric acid, 18% ethanol and 2% Coomassie Brillant 
Blue G-250). The gels were immersed in the hot Colloidal Coomassie 
solution and left shaking overnight. Gels were then scanned on the 
Scanner Image III (GE Healthcare) and stored in cellophane until use for 
MS. 
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3.3.4. Image analysis  
Coomassie-stained gels at high resolution (300 dpi) images were scanned 
with ImageScanner™ III (GE Healthcare) and were acquired using the 
LabScan 6.0 software; the image analysis was analyzed using Image 
Master 2D Platinum software III (GE Healthcare) of University of Cagliari 
and Progenesis SameSpots (Nonlinear Dynamics) of University of Vigo. 
In all experiments, two replicates from both the control and fibromialgic 
samples were used. A single gel was selected as a master gel and all the 
other gels were matched against this gel. The gels were normalized by the 
software based the total volume of a gel. The protein spots that visually 
appeared as technical artifacts (e.g., background areas of Coomassie 
staining, irregularly shaped dust particles, air bubbles), but were 
erroneously detected by the software, were manually removed from the 
analysis. 
3.3.5. Statistical analysis 
The optical density of the proteins was expressed as a percentage of the 
volume (mean±SD) with ImageMaster III (GE Healthcare) software. For 
each gel, the preliminary analysis included protein spot detection, editing, 
filtration and quantification. Spots were quantitated as a fraction of the 
total volume of protein spots on the gel. One typical control gel with the 
most protein spots was then set as reference gel, to which all the other gels 
were matched. Match rates of each group of gels were calculated 
automatically by the software. The non-parametric, Mann–Whitney test 
was used for analysis of the mean intensity differences of the spots 
between normal and FMS gel groups. p values ≤ 0.05 were considered as 
significant differences. 
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Gels were processed also with Progenesis SameSpots software (Nonlinear 
Dynamics, Newcastle upon Tyne, UK), where quantitative analysis of 
protein spots was performed. Following automatic and subsequent manual 
editing, aligning and matching procedures as part of the Progenesis 
SameSpot workflow, ANOVA p-values between the samples were 
calculated within the Progenesis SameSpot software, which computed the 
fold change (the fold difference of logarithms of normalized spot volumes 
between the patient and control groups; the average values of normalized 
spot volume logarithms of a single spot in all samples within a group are 
compared) and p-values of all spots using one-way ANOVA analysis. One 
way to adjust for multiple comparisons is to consider the false discovery 
rate (FDR), which is the probability that a spot determined to be 
significantly different is, in fact, a false discovery. To account for multiple 
comparisons, p-values were adjusted by the FDR controlling method 
computed in automatic by software, obtaining the corresponding q-values. 
Principal Component Analysis (PCA) was performed to assess whether 
grouping of patients and healthy controls based on proteomic methods 
reflects their stratification using classical clinical diagnosis. PCA was 
performed making use of the same software, focusing only on the spots of 
statistical significance (based on 2D SDS-PAGE) employed for protein 
identification.  
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3.3.6. Mass spectrometry 
3.3.6.1. In gel digestion and MS analysis  
Protein spots of interest were identified by the National Council of 
Researches (CNR), Institute of Molecular Sciences and Technologies 
(ISTM) of Padova. The spots were manually excised from 2-DE gels 
following the procedure described and adapted from Shevchenko A et al, 
1996.  The spots were washed (25 mM ammonium bicarbonate), 
dehydrated (25 mM Ambioc/50% acetonitrile (ACN) followed by 100% 
ACN), reduction (10mM DTT/25mM NH4HCO3) and alkylation (55mM 
IAA/ 25mM NH4HCO3), dried, and enzymatically digested with sequence-
grade modified porcine trypsin (Sigma) overnight. Peptides from gel-
trypsin digestion were desalted and concentrated by Supel TipsU-C18 
(Sigma), following the procedure described in the user’s guide. Proteins 
identification was performed by peptide-mass fingerprint MALDI/MS 
measurements using a MALDI-TOF/TOF UltrafleXtreme (Bruker 
Daltonics, Bremen, Germany), equipped with 1 kHz smartbeam II laser (λ 
= 355 nm) and operating in the positive reflectron ion modes. The 
instrumental conditions employed to analyze molecular weight in the m/z 
range 980-7000 were: Ion Source 1: 25.00 kV; Ion Source 2: 22.40 kV, 
Lens: 8.00 kV, Reflector: 26.45 kV, Reflector 2:13.45 kV, Pulsed ion 
extraction: 120 ns. The matrix employed was α-cyano-4-hydroxycinnamic 
acid (HCCA) (saturated solution in H2O/Acetonitrile (50:50; v/v) 
containing 0.1% TFA). External mass calibration was done using the 
Peptide Calibration Standard, basing on the monoisotopic values of 
[M+H]
+
 of Angiotensin II, Angiotensin I, Substance P, Bombesin, ACTH 
clip (1-17), ACTH clip (18-39), Somatostatin 28 at m/z 1046.5420, 
1296.6853, 1347.7361, 1619.8230, 2093.0868, 2465.1990 and 3147.4714 
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respectively. The instrumental conditions employed for the TOF/TOF 
experiments on the ion at m/z 2694 were: Ion Source 1: 7.5 kV, Ion 
Source 2: 6.75 kV, Lens: 3.5 kV, Lift Voltage 1: 19 kV, Lift Voltage 2: 
2.9 kV, Reflector Voltage 1: 29.5 kV, Reflector Voltage 2: 13.95 kV. The 
peptide masses were searched against the National Center for 
Biotechnology Information nonredundant mammalian database using 
Mascot 2.3 searched from Matrix Science, selecting the Swiss-Prot 
database. For the present study, protein identification was based on the 
measurement with a Mascot score higher than 55. Minimal expectation for 
valid identification was p < 0.005 and p < 0.05. 
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3.4. Analysis of serum metabolites 
3.4.1. HPLC 
The samples  were centrifuged at 10000 x g for 5 min through cellulose 
acetate spin filters (0.2 μm, VectaSpin Micro, Whatman) to remove 
particulate matter and lipids. 
HPLC analysis was performed using Agilent Technologies 1100 series 
HPLC, supplied with a binary pump and diode array detector (DAD).  
Six purine reference standards (uric acid, hypoxanthine, xanthine, inosine, 
guanosine and adenosine) were used, all of the highest analytical grade 
available (Sigma-Aldrich, Milan, Italy; Across Organics, Geel, Belgium). 
Chromatographic separation of purine metabolites was obtained using a 
reverse-phased column (Agilent Zorbax 300 SB-C18, 250×4.6 mm, 5 μm). 
Two eluents were used for compound separation: solvent A=KH2PO4 25 
mM (in MilliQ water) and solvent B=a mixture of 75% solvent A and 25% 
methanol. Elution was performed with a flow rate of 600 μl/min: 0–6 min, 
0%B; 6–19 min, linear gradient 0–80% B; 19–22 min 80% B; 22–26 min, 
0% B. HPLC experiments lasted 26 min. Analytes were detected at 254 
nm at six specific retention times, and peak areas were compared to those 
of specific calibrators that were prepared immediately prior to use. 
All determinations were performed in triplicate and each sample 
concentration is expressed as mean. 
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3.4.2. Statistical analysis 
Statistical analysis was performed using STAT VIEW 5.0 by SAS 
Institute Inc. The mean and error standard (SE) of the mean was calculated 
for each variable. Differences between the groups were calculated using 
the Student's t-test. Pearson's correlation was calculated to test the 
relationship between parameters examined in the FMS patients. There was 
no evidence of non-normality among the outcome variables according to 
the Kolmogorov–Smirnov test. 
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4. RESULTS 
4.1. Clinical parameters 
Demographic characteristics and clinical parameters of FMS and control 
subjects are reported in table 5 (for analysis purine metabolite) and 6 (for 
analysis proteome). No associated clinical distresses or pain were reported 
in the control subjects (VAS pain=0). 
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 FMS 
 (n= 22) 
Controls 
(n= 22) 
Age [years, mean (DE), range] 53.5±2.3 
(27-72) 
49.7±2.3 
(27-67) 
Sex females females 
Menopause  n=15 n=11 
Body Mass Index (m
2
/Kg)(mean + SD) 25.8 ± 0.94 23.3 ±0.54 
Pain duration (years, mean + SE) 5.1 ± 0.5 - 
Pain score patient (VAS mm) (mean ± SE) 56.8 ± 5.8 - 
Pain score physician (VAS mm) (mean ± SE) 36.2 ± 3.9 - 
FIQ total score (0-80) (mean ± SE) 63.1 ±4.2 - 
Associated Clinical Distresses   
Tension type headache n=17  
Irritable colon n=15 - 
Oto vestibule syndrome n=14 - 
Paraesthesia n=14 - 
Sleep disturbance n=13 - 
Dysmenorrhea n=11  
Hemicrania n=7  
Urethral syndrome n=7  
Medication   
No therapy n=5 n=22 
   
Paracetamol n=13  
Tricyclic n=9 - 
Selective Serotonin Reuptake Inhibitors (SSRIs) n=2 - 
Selective Serotonin Noradrenaline Reuptake 
Inhibitors (SSNRIs) 
n=6 - 
Table 5. Characteristics and scores of examined subjects for analysis purine 
metabolite 
 
(FMS = fibromyalgia syndrome; FIQ = FMS impact questionnaire; VAS 
= visual analogue scale. 
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 FMS 
 (n= 16) 
Controls 
(n= 12) 
Age [years, mean (DE), range] 52 ± 12  
(27-72) 
48 ± 13  
(27-67) 
Sex females females 
Menopause  n=10 n=5 
Body Mass Index (m
2
/Kg)(mean + SD) 27 ± 5 24 ± 3 
Pain duration (years, mean + SE) 4.9 ± 0.5 - 
Pain score patient (VAS mm) (mean ± SE) 57 ± 31 - 
Pain score physician (VAS mm) (mean ± SE) 34 ± 18 - 
FIQ total score (0-80) (mean ± SE) 61.8 ± 21.9 - 
Associated Clinical Distresses   
Tension type headache n=12  
Irritable colon n=9 - 
Oto vestibule syndrome n=9 - 
Paraesthesia n=8 - 
Sleep disturbance n=8 - 
Dysmenorrhea n=2  
Hemicrania n=4  
Urethral syndrome n=5  
Medication   
No therapy n=4 n=12 
   
Tricyclic n=6 - 
Selective Serotonin Reuptake Inhibitors (SSRIs) n=1 - 
Selective Serotonin Noradrenaline Reuptake 
Inhibitors (SSNRIs) 
n=4 - 
Table 6. Characteristics and scores of examined subjects for analysis proteome 
(FMS = fibromyalgia syndrome; FIQ = FMS impact questionnaire; VAS = visual 
analogue scale. 
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4.2. Proteomics data analysis 
4.2.1. Proteome profile of serum 
Using Image Master 2D Platinum software (GE) of University of Cagliari 
and Progenesis SameSpots (Nonlinear Dynamics) of University of Vigo, 
we compared 2D maps of sera between sixteen patients FMS and twelve 
healthy controls. The images of gels were found to be similar between 
groups. The results were satisfactory: the number of protein spots in each 
gels of the same group was stable and the average spot positional 
deviations were slight. There were approximately more than 100 spots that 
could be visualized manually in the 2D gel images of both FMS patients 
and controls. Simultaneously, 88 ± 23 spots were detected for control gels 
and 119 ± 26 for patient gels using Image Master 2D Platinum Software 
(GE).  
Using Progenesis SameSpots (Nonlinear Dynamics) all two groups were 
mutually compared using one way ANOVA analysis. Both manual and 
automatic image alignment were used. Specific pre-filtering and statistical 
criteria were applied to all spots that were automatically detected by the 
Progenesis SameSpots software (in total more than 2200 spots detected by 
the software). Applying pre-filtering (edge and area exclusion, minimal 
spot area, or normalized volume) altogether more than 151 spots remained 
in the analysis. In Figure 7 is presented a typical control gel (A) and a 
typical patient gel (B).Using statistical criteria in the next step (Anova p < 
0.05, FDR smaller than 7%; minimum fold change 1.2), we detected 17 
spots that significantly differed in the normalized volumes; positions of 
these spots are highlighted in figure 8. In figure 9 shows the enlarge 
images of 106, 1065 and 2334 spot differentially expressed found in 
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different quantity in FMS respect to control. Principal Component 
Analysis showed an evident separation of samples into two aggregates, 
corresponding to the FMS and control groups (Figure 10). 
 
 
 
 
 
  
77 
 
 
A         B 
                                                                          
                           3      IPG                        10            3  IPG      10 
  
Figure 7. Representative 2-DE gel map of control (A) and fibromyalgic (B) serum proteins. 
The protein samples were loaded onto linear IPG strips (pH 3-10, 18 cm) in an IEF cell and then separated by 10% SDS-
PAGE. The protein spots were visualized by Colloidal Coomassie Brillant Blue G-250 stain. 
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Figure 8. The map was analyzed by the Progenesis SameSpots (Nonlinear 
Dynamics) Software. Spot numbers indicate all the proteins differentially 
expressed in FMS with respect to the control. 
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SPOT ID 106 
  
80 
 
SPOT ID 1065 
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SPOT ID 2334  
Figure 9. Enlarged images of the 2-DE gels represent proteins spots and expression profiles with the logarithms of spot normalized 
volumes and their standard deviations showing statistically significant changes between controls and FMS for six representative gels. 
Gel areas containing the same spot from each group (three exemplary gel area from each group) are presented above the logarithm 
values. Data were obtained from 2-DE gels using Progenesis SameSpots (Nonlinear Dynamics) Software.  
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Figure 10. Principal Component Analysis. PCA was performed to assess whether grouping of patients and healthy controls based on 
proteomic methods reflects their stratification using classical clinical diagnosis. Analysis was based on spots that significantly differ 
according the mentioned statistical criteria (p<0.05, ANOVA and q<0,07, FDR). Principal Component Analysis (PCA) showed the 
separation of all samples into two aggregates that corresponded to the FMS (blue dots) and the control group (pink dots). 
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4.2.2. Characterization of differentially expressed proteins 
After normalization, volume calculation, and statistical analysis with the 
Progenesis Samespots software, three spots (106, 1065 and 2334) were 
chosen for Mass Spectrometry/Mass Spectrometry (MS/MS) analysis and 
were characterized. The MALDI spectra obtained by the trypsin digestion 
of the 2D gel spots are reported in Figure 11. Table 6 shows the 
characteristics of the identified proteins, including the number of peptides 
matched, the percent coverage, the pI, the MW, the accession number, the 
score, the matched sequence and the fold change. To confirm the results 
has been performed MS/MS:MS/MS analysis has been performed in order 
to obtain the fragmentation spectra (Table 7). In practice, each m/z (mass-
to-charge ratio) of interest (precursor ion) was selected and its fragments 
(product ions) were simultaneously detected. The peaks list has been used 
for peptides/proteins identification via on-line search engines such as: 
Mascot (http://www.matrixscience.com) and MS-Tag 
(http://prospector.ucsf.edu). MS/MS analysis has been indicated the same 
proteins confirming the results of MS. The search for the Peptide Mass 
Fingerprinting obtained for spot ID1065 and spot ID 106 in the Mascot 
database allow their identification: spot ID1065 is due to Transthyretin 
(TTR), spot ID 106 is due to Alpha-1 Antitrypsin (A1AT). These 
identifications were confirmed by MS/MS experiments on selected 
peptides present in the tryptic digestion mixture of each spot. In the case 
of spot ID 2334, only through MS/MS experiments on selected digestion 
products ions (m/z 2694 and m/z 2018) and by search in Mascot database 
it was possible to identify the protein as Retinol Binding Protein 4 
(RBP4). All 3 proteins identified in this study were categorized into 
different cellular functional groups based on the available literature and 
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the protein databases Pfam http://pfam.sanger.ac.uk and/or InterPro 
http://www.ebi.ac.uk/interpro/ (Apweiler R et al, 2001). 
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Figure 11. Representative peptide MS spectra from three proteins differentially 
expressed.  
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Spot ID Methods Protein name Short  
name 
Accession  
number 
Mw  
(KDa) 
pI Score Coverage 
(%) 
p-value Fold-
increase 
106 MS/MS Alpha-1-antitrypsin A1AT P01009 46 5.27 91 51% 3,228e-
005 
2,0 
1065 MS Transthyretin TTR P02766 15 5.81 121 100% 0,007 1,3 
2334 MS Retinol-binding 
protein 4 
RBP4 P02753 23 5.8 70 12% 0,039 1,2 
Table 6. Protein identification of differentially expressed proteins in serum of FMS patients identified by MALDI-TOF/TOF MS 
analysis. 
Spot ID Protein name Mr(expt)
a
 Mr(calc)
b
 Score Sequence 
106 Alpha-1-antitrypsin 1333.7927 1332.7653 40 K.LVDKFLEDVKK.L 
  1833.9927 1832.9156 91 K.VFSNGADLSGVTEEAPLK.L 
  2161.9927 2161.1266 127 K.VFSNGADLSGVTEEAPLKLSK.A 
  3147.9927 3147.5149 57 K.GKWERPFEVKDTEEEDFHVDQVTTVK.V 
1065 Transthyretin 1393.9927 1393.6150 85 K.AADDTWEPFASGK.T 
  1521.9927 1521.7100 108 R.KAADDTWEPFASGK.T 
  2449.9927 2450.1979 102 K.ALGISPFHEHAEVVFTANDSGPR.R 
  2607.0000 2605.2990 92 K.ALGISPFHEHAEVVFTANDSGPRR.Y 
  3138.9927 3139.5085 65 K.TSESGELHGLTTEEEFVEGIYKVEEIDTK.S 
2334 Retinol-binding protein 4 2018.2726 2016.9920 78 R.LIVHNGYCDGRSERNLL.N 
  2694.0000 2692.9927 70 K.GNDDHWIVDTDYDTYAVQYSCR.L 
Table 7. Identified peptides by MSMS analysis using the Mascot software.  
a
 Mr(expt), nominal mass calculated from the measured m/z;
b
 Mr(calc), Mr of the matched peptide.  
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4.3. Serum purine metabolites 
The chromatograms obtained during RP-HPLC were analyzed and the 
quantitative analysis was obtained. Serum purine levels in FMS subjects 
versus controls, magnitude of the changes and statistical significance are 
reported in Table 8. 
 Fibromyalgia Controls Difference  Significance 
Uric acid  
RT=9.34±0.37 
315.46±16.80 318.40±28.03 −2.93 p=0.93 
 
Hypoxanthine 
RT=11.55±0.32 
79.57±6.86 11.99±0.87 67.58 p=0.0001 
 
Xanthine 
RT=12.95±0.24 
5.08±0.36 1.71±0.15 3.37 p=0.0001 
 
Inosine 
RT=17.83±0.36 
40.58±3.73 7.07±1.33 33.51 p=0.0001 
Guanosine 
RT=18.27±0.44 
1.58±0.20 1.78±0.27 −0.20 p=0.54 
 
Adenosine 
RT=21.96±0.86 
0.29±0.008 1.22±0.36 −0.93 p=0.013 
 
Table 8. Serum purine metabolites (μmol/L, mean±SE) in examined subjects. 
RT=retention time (min). 
The relationships between FIQ and serum purine metabolites in FMS are 
reported in Table 9; serum adenosine levels are significantly correlated 
with FIQ. 
FIQ and Pearson's correlation 
coefficient 
Significance 
p 
 
Uric acid 0.16 0.48 
Ipoxanthine 0.24 0.29 
Xanthine 0.40 0.06 
Inosine 0.10 0.68 
Guanosine 0.04 0.85 
Adenosine −0.46 0.03 
 
Table 9. Pearson correlation among examined parameters.  
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5. DISCUSSION 
5.1. Proteomics  
Recently, a proteomic approach has been used to identify potential 
biomarkers of FMS in salivary fluid (Giacomelli C et al, 2011). However, 
to the best of our knowledge, no such study has been reported on sera of 
FMS patients. In this study, we attempted a proteomic approach such as 2-
DE and MALDI-TOF MS to evaluate serum protein profile in FMS 
patients and in matched healthy controls. Our data showed three 
differentially expressed protein spots identified as Transthyretin (TTR), 
Retinol Binding protein 4 (RBP4) and Alpha-1 Antitrypsin (A1AT). 
Transthyretin (TTR) (spot ID 1065) gene is located at chromosome 
18q11 and consists of four exons (Tsuzuki T et al, 1985). TTR is a 
homotetrameric protein of 55 kDa mainly synthesized in the liver, that is 
responsible for more than 90% of TTR synthesis which is secreted into the 
blood. In addition to the liver, other sites of TTR synthesis have been 
identified in mammals: choroid plexus (Aleshire SL et al, 1983), retinal 
pigment epithelium (Martone RL et al, 1988) and pancreas (Schreiber G et 
al, 1990). Recent data (Li X, et al 2011) indicate that there is also a 
neuronal production of TTR. TTR has specific binding sites for Thyroxine 
(T4), RBP4 and also for Amyloid beta 1-42 (Aβ1-42); it is also the plasma 
transporter of T4 and retinol (Raz A et al, 1969), in the latter case through 
binding to the RBP4, and it has been suggested that TTR may be one of 
the Aβ1-42 sequestering proteins in CSF (Li X et al, 2011). In mammals 
TTR also binds T3 but with lower affinity. Thyroid hormones are essential 
for development, growth, metabolism, fertility, cardiovascular system and 
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brain function. TTR transports about 20% of the hormone T4 in the 
plasma (Myron JA et al, 2007) and 80% in the CSF (Robbins J, 1991).  
RBP4 is transported in the bloodstream, attached to TTR only when bound 
to retinol as a 1:1 molar protein complex (Goodman DS, 1984; Blaner 
WS, 1989; Raz A et al, 1970). TTR association to RBP4 protects it from 
glomerular filtration and renal catabolism (Raghu P et al, 2004; 
D’Ambrosio DN et al, 2011) and from oxidation. Retinol or vitamin A is 
essential for vision, reproduction, growth, differentiation and metabolism. 
After retinol delivery to tissues, RBP4 shows a reduced affinity to TTR. 
At target cells the vitamin dissociates from RBP4 and readily moves into 
cells by diffusion across the plasma membrane according to concentration 
gradient (Noy N et al, 1990). TTR has been associated with a number of 
pathological conditions, including Alzheimer's disease, Parkinson's 
disease, schizophrenia and depression (Fleming CE et al, 2009). Other 
reports suggested that TTR was associated to several types of cancer, 
diabetes, rheumatoid arthritis, glomerular disease and hepatitis. Moreover, 
TTR is thought to be directly and causally involved in the establishment of 
all stages of the stress response to nutritional impairment and in acute 
stressful conditions, such as tissue injury. In relation to this, the serum 
TTR level (0.08-0.45 mg/ml) is used as a marker for malnutrition as well 
as inflammation, decreasing in both clinical settings (Myron JA et al, 
2007). Its serum level is decreased in patients with some tumors (Kozak 
KR et al, 2005, Liu L et al, 2007), although it is not clear whether such 
decrease is related to an inflammatory response or is an intrinsic property 
of the tumors. Maetzler W and co-workers (2012) reported that CSF TTR 
values rise in response to oxidative stress. Significantly increased TTR 
serum levels were detected in high myopia patients compared to healthy 
controls (Shao J et al, 2011). The physiological role of TTR in the eye is 
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not completely known, but it may participate in retinol cycling. An 
elevated number of TTR mutations is known (Saraiva MJM, 2004). Most 
of the variants result from point mutations in the polypeptide chain, except 
the case of a deletion of one aminoacidic residue at position 122. The 
majority of the TTR variants are associated with peripheral neuropathy, 
often presenting cardiomyopathy, carpal tunnel syndrome (CTS) and 
vitreopathy. In FMS may mask that CTS can be an associated illness in 
fact Nacir B et al, (2012) find a higher frequency of CTS in FMS patients. 
Terazaki H et al, (1999) described an interesting compound heterozygote 
in the TTR gene with familial amyloidotic polyneuropathy (FAP). The 
total TTR and RBP4 concentrations in the serum samples of the proband 
were higher than in control subjects. The mutation may play a suppressing 
role in amyloid formation since none of the family members of the present 
case carrying the mutated gene showed clinical symptoms of FAP. 
 
Retinol binding protein 4 (RBP4) (spot ID 2334) is the specific blood 
carrier for the transport of retinol (Vitamin A) to target tissues; it is a 21 
kDa monomeric protein comprising 182 aa residues (Rask L et al, 1979). 
RBP4 is mainly synthesized in the liver (Goodman DS, 1984), but several 
extrahepatic organs have been found to contain high amounts of the 
protein (Soprano DR et al, 1986). As reported above, RBP4 circulates in 
the bloodstream as a complex with TTR, which increases the molecular 
mass of RBP4 complex and thus prevents its glomerular filtration (Raghu 
P et al, 2004; D’Ambrosio DN et al, 2011). Recently, Raghu P et al, 
(2012) found that elevated levels of plasma RPB4 in obesity and type 2 
diabetes (T2D) could be due to either increased RBP4 expression in the 
adipose tissue or increased plasma TTR levels or both. TTR probably 
serves as a regulatory checkpoint for insulin function by modulating 
91 
 
plasma RBP4 levels. Akkus S et al (2009) found decreased Vitamin A 
concentration in FMS than in controls and supposed an imbalance between 
the reactive oxygen species (ROS) production and the antioxidant defense 
system in these patients.  
Alpha-1 antitrypsin (spot ID 106), a member of the SERPINs (SERine 
Proteinase Inhibitor) superfamily, is a 52 kD glycoprotein serine 
proteinase inhibitor mainly produced by hepatocytes (Blank CA et al, 
1994), with smaller amounts synthesized by intestinal epithelial cells, 
neutrophils, pulmonary alveolar cells, and macrophages (Aldonyte R et al, 
2004, Dabbagh K et al, 2001). A1AT concentrations in healthy subjects 
are 1.5-3.5mg/ml and can increase fourfold during inflammation, 
indicating that A1AT is an acute-phase protein (Blank CA, 1994; Carrell 
RW et al, 1986; Massi G et al, 1994). Its major function is the inhibition of 
overexpressed serine proteases (American Thoracic Society, 2003; 
Janciauskiene S et al, 2007). A1AT is also known to regulate the 
activation and apoptosis of neutrophils, monocytes, endothelial, and 
pancreatic cells acting as an antioxidant, modulating cell-mediated 
immunity tolerance and cellular innate immune response and neutralizing 
endotoxin-mediated inflammation. Moreover, A1AT could play a role in 
host cell defense against microbial pathogens (Cordelier P et al, 2003; 
Forney JR et al, 1997). Adding A1AT to cultured human cells in vitro has 
revealed anti-inflammatory properties. A1AT inhibited LPS-stimulated 
(Lipopolysaccharide) synthesis and secretion of TNF-α and IL-1β in 
human blood monocytes (Janciauskiene SM et al, 2004). In addition, 
intracellular signaling studies showed that A1AT inhibited activation of 
NF-kB, a transcription factor involved in the expression of several 
proinflammatory cytochines (Shapiro L et al, 2001). A1AT gene is located 
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in chromosome 14 and has two alleles, named by the letters of the 
alphabet. Normal alleles are called M and are found in about 80% of 
individuals (American Thoracic Society, 2003); most common abnormal 
alleles are called S and Z. Blanco I et al (2007) suggest that a subset of 
FMS lacking functionally active A1AT may suffer from inflammatory 
processes, mediated by proteases, cytokines, oxidants, and other 
inflammation mediators normally regulated by A1AT. Therefore, the 
inherited deficiency of A1AT may constitute a genetic modifier of the 
expression of FMS syndrome. In another study Blanco I et al, (2010 Feb) 
showed higher A1AT plasma concentrations in the MM A1AT subject in 
the FMS group than those in the general population groups. No 
histological differences were found between samples from A1AT 
deficiency and normal A1AT phenotypes, but a significantly increased 
number of mast cells (MCs) in the papillary dermis of all FMS patients 
contained moderately high levels of A1AT. MCs are present in skin and 
mucosal surfaces throughout the human body, and are easily stimulated by 
a number of physical, psychological, and chemical triggers to degranulate, 
releasing several proinflammatory products which are able to generate 
nervous peripheral stimuli causing CNS hypersensitivity, local and 
systemic symptoms (Blanco I et al, 2010 Dec). High serum levels of 
A1AT have been reported in hepatocellular carcinoma (HCC) but the 
exact mechanism and role of these findings is still unclear. Results of the 
study by Sawaya R et al, (1987) supported hypotheses that the production 
of A1AT by tumor cells correlates with the regional proteolytic and 
inflammatory activity, which are probably involved in the protection of 
tumor cells. In addition to its antiprotease activity, there are evidence that 
A1AT molecule has a relevant antioxidant capacity. AAT has one cysteine 
and nine methionine residues; the sulfur groups of two of the methionines 
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and cysteine thiol group are potentially available for interaction with 
oxidant (Taggart C et al, 2000; Brantly M, 2002). 
To the best of our knowledge, no proteomic study has been reported on 
sera of FMS patients; in this preliminary study, we described, for the first 
time, the human serum protein pattern of FMS patients in comparison with 
healthy controls in order to identify the potential biomarkers for the 
disease. 
In pathogenesis of FMS oxidative stress has been proposed as a relevant 
event (Cordero MD et al PLOS one, 2011). The reactive oxygen species 
(ROS) are one the main products source of oxidative stress; mitochondria 
are one of the major sources of ROS (Raha S et al, 2000) and can generate 
ROS as byproducts of molecular oxygen consumption in the electron 
transport chain. Also if the role of ROS in FMS is controversial (Akkus S 
et al, 2009), Cordero and co-workers (2013) underline an important role of 
oxidative stress and mitochondrial dysfunction in FMS.  
There is a complex defense system protecting from oxidative stress 
including enzymes and non-enzymatic species such vitamin C, E and A 
(Zingg JM et al, 2004, Chiu HJ et al, 2008). Vitamin A regulates multiple 
cellular processes and exerts many of its biological activities by giving 
rise to active metabolites (11-cis-retinaldehyde and retinoic acid); it is 
stored in various tissues mainly in the liver and it is secreted from storage 
into the circulation bound to retinol-binding protein 4 (RBP4); in most 
mammalians Vitamin A-bound RBP4 is associated to transthyretin (TTR) 
in a complex that, under normal circumstances, displays a 1:1 molar 
stoichiometry. 
Vitamin A deprivation causes a rapid increase in mitochondria-derived 
ROS and results in cell death consequent to mitochondrial membrane 
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depolarization and rapid loss of plasma membrane integrity (Chiu HJ et al, 
2008). Discordant data are reported on Vitamin A levels in FMS patients 
(Eisinger J et al, 1997); Akkus S et al, (2009) showed a reduction of 
Vitamin A in FMS patients as results of its role action on radical inhibition 
and hypothesized an imbalance between ROS production and the 
antioxidant defense system in patients with fibromyalgia. 
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5.2. Purine metabolites 
A prevailing theory in the pathogenesis of FMS is the dysregulation of 
pain pathways leading to central sensitization and marked by 
neurotransmitter, neurohormone and sleep physiology irregularities 
(Mease P, 2005). 
Consensus of opinion exists regarding a widespread physiological and 
pathological role played by purines acting via extracellular receptors and, 
a number of recent studies implicate the purinergic system as essential for 
pain transmission (Sawynok XJL, 2003). The role of extracellular purine 
on pain transmission has been investigated (Sawynok XJL, 2003), but 
clinical studies correlating purine levels and pain are limited. Some 
authors report that fibromyalgia could include dysfunction of purine 
nucleotide metabolism and nociception (Guieu R et al, 2012); adenosine 
exerts antinociceptive effects when released into the extracellular space. 
Extracellular inosine and adenosine access the cell through equilibrative 
and concentrative transporters and adenosine and inosine compete for 
these transporters (Pastor-Anglada M et al, 2001); high extracellular 
inosine can lead to an increase in extracellular adenosine preventing 
adenosine uptake. In this context, adenosine deaminase (ADA) activity 
might play an essential role. ADA is an enzyme that catalyzes deamination 
of either adenosine or deoxyadenosine. Adenosine is converted to inosine 
by ADA. This reaction is one of the rate limiting steps in adenosine 
degradation due to its irreversibility. ADA activity is altered in various 
diseases (Urunsak IF et al, 2012). Following extracellular release, all 
purine nucleotides and nucleosides undergo a complex extracellular 
metabolism by many cell surface located enzymes (Rathbone MP et al, 
1999). ADA may play a focal role in this way; ADA exerts metabolic 
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functions inside the cells but, outside the cells, it also has extra enzymatic 
effects involving modulation of adenosine A1 receptors (Ciruela F et al, 
1996). The presence of increased ADA activity to explain inosine 
concentrations higher than adenosine has been reported in isolated rat 
hepatocytes after hypoxia (Guinzberg R et al, 2006). Moreover, recent 
data (Guieu R et al, 2012) show that low extracellular adenosine 
concentration in FMS is modulated by a complex of CD26 
(multifunctional glycoprotein with dipeptidylpeptidase IV activity) in 
association with MCADA (mononuclear cell adenosine deaminase 
activity). Adenosine is recognized as an important modulator of 
neurotransmission and has been implicated in many physiological 
functions such as sleep and anxiety regulation, typical distresses in FMS: 
Sawynok XJL, (2003) reported that spinal administration of adenosine 
produces analgesia in patients with central sensitization.  
 
  
97 
 
6. CONCLUSION  
Our study revealed overexpression of TTR, A1AT and RBP4 in FMS 
patients compared to control subjects. Our data show increased serum 
RBP4; upregulation of RBP4 may induce hypovitaminosis A (Chuang MC 
et al, 2012). High serum TTR and RBP4 might be consequent to a flow 
out from the cells due to ROS mediated alteration of membrane integrity 
or permeability; in fact in vivo experiments have suggested that RBP4 
accumulates also in vitamin A-deficient hepatocytes but it is not secreted 
into bloodstream (Ronne H et al, 1983). 
In our study we found also an overexpression of serum A1AT. Also 
Blanco et al 2010 reported high A1AT plasma concentrations in a subset 
of FMS patients and a significantly increased number of mast cells (MCs) 
in the papillary dermis of all FMS patients with moderately high levels of 
A1AT (Blanco I et al, 2010). The mastocyte-released chemicals could 
cause local manifestations (e.g. skin tenderness or pain) that might be 
related to enhanced pain sensitivity of these patient.  
A1AT is one of major circulating inhibitor of proteases but it is well 
known that it is the target of reactive oxidants (Ueda M et al, 2002). 
Previous study (Marzatico F et al, 1998) reported slight increase of A1AT 
associated to decrease of vitamin A suggesting that genetic or 
environmental factors may influence the activity of A1AT and that the 
activity of A1AT is dependent on the antioxidant capacity of liposoluble 
vitamins. A1AT can be oxidized by free radicals released from oxidative 
stress, resulting in protein dysfunction that leads to the imbalance between 
A1AT and proteases, which can cause tissue damage (Jamnongkan W et 
al, 2012). Then there may be high levels of A1AT (as reported in our 
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study) but with ineffective action as protease inhibitor but might act as an 
antioxidant.  
Considering that the TTR and RBP4 are both retinoid transporters, 
retinoid dysfunction is related to oxidative stress as well as A1AT. 
In purine study, our data show an increase of serum inosine, hypoxanthine 
and xanthine and a decrease of adenosine in FMS subjects. In this context, 
adenosine deaminase (ADA) activity might play an essential role. In FMS, 
ADA activity might be increased and consequently convert almost all 
adenosine to inosine, unbalancing their extracellular concentrations. 
Moreover, significantly lower serum adenosine levels in FMS subjects 
with respect to controls are confirmed by recent data reported by Guieu et 
al (2012). Furthermore, adenosine is recognized as an important modulator 
of neurotransmission and has been implicated in many physiological 
functions such as sleep and anxiety regulation, typical distresses in FMS, 
and our data show a negative correlation of adenosine with the patients’ 
clinical feature (FIQ) that is consistent with enhanced pain sensitivity in 
FMS patients; in fact adenosine is associated with the mechanisms 
underlying pain transmission, consequently, low plasma adenosine, acting 
at a peripheral level, supports the low nociceptive threshold in these 
patients where pain is a principal symptom in FMS. Moreover oxidative 
stress in FMS might be consistent with these data that showed unexpected 
normal levels of uric acid despite high levels of inosine, hypoxanthine, 
xanthine in FMS patients. Uric acid is a powerful free radical scavenger in 
humans (Waring WS, 2002) then might be not increased in FMS patients 
due to its consumption as ROS scavenger. 
Our results are consistent with the underlying hypothesis that there is an 
imbalance between ROS production and the antioxidant defense system of 
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patients with fibromyalgia. The oxidative stress in FMS might increase 
serum TTR, RBP4 and A1AT expression and utilize uric acid as ROS 
scavenger. Moreover, adenosine is associated with the mechanisms 
underlying pain transmission, where the pain is a principal symptom in 
FMS.  
Further investigation will be required to confirm this observation. 
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APPENDIX: Italian FIQ 
 
FIBROMYALGIA IMPACT QUESTIONNARIE 
FIQ 
ISTRUZIONI: nelle domande dal numero 1 al numero 11 del questionario 
che segue, verranno poste delle domande riguardo alle attività che si è stati 
in grado di svolgere nell’ultima settimana. 
Rispondere a ciascuna domanda, mettendo una crocetta nella casella 
corrispondente (solo una risposta per ciascuna domanda). 
Se normalmente non si svolge l’attività cui la domanda si riferisce, barrare 
l a casella 4 
NEL CORSO DELL’ULTIMA 
SETTIMANA E’ STATO IN 
GRADO DI 
SEMPRE 
 
0 
QUASI 
SEMPRE 
1 
QUALCHE 
VOLTA 
2 
MAI 
 
3 
ATTIVITA’  
NON SVOLTA  
ABITUALMENTE 
 
1) ANDARE A FARE 
LA SPESA 
0 1 2 3 4 
2) FARE IL BUCATO 
(LAVATRICE) 
0 1 2 3 4 
3) PREPARARE I 
PASTI 
0 1 2 3 4 
4) LAVARE I PIATTI 0 1 2 3 4 
5) PASSARE 
L’ASPIRAPOLVERE 
0 1 2 3 4 
6) RIFARE I LETTI 0 1 2 3 4 
7) CAMMINARE PER 
QUALCHE ISOLATO  
0 1 2 3 4 
8) ANDARE A FAR 
VISITA A PARENTI  O AMICI 
0 1 2 3 4 
9) FARE LAVORI DI 
GIARDINAGGIO – ORTO 
0 1 2 3 4 
10) GUIDARE L’AUTO 0 1 2 3 4 
11) SALIRE LE SCALE 0 1 2 3 4 
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12) QUANTI GIORNI SU 7 DELL’ULTIMA SETTIMANA SI E’ 
STENTITA BENE? 
0 1 2 3 4 5 6 7 
 
13) QUANTI GIORNI SU 7 DELL’ULTIMA SETTIMANA NON E’ 
ANDATA A LAVORO O NON HA POTUTO FARE LAVORI 
DOMESTICI A CAUSA DELLA FIBROMIALGIA? 
0 1 2 3 4 5 6 7 
 
Risponda alle seguenti domande apponendo un segno sulla riga 
sottostante  
(estrema sinistra = nessun problema estrema destra = massima 
difficoltà) 
14) SUL POSTO DI LAVORO O A CASA DURANTE I LAVORI 
DOMESTICI, QUANTA DIFFICOLTA’ HA AVVERTITO A CAUSA DEL 
DOLORE O DEGLI ALTRI SINTOMI DELLA FIBROMIALGIA? 
____________________________________________________________ 
 
15) QUANTO E’ STATO FORTE IL SUO DOLORE? 
____________________________________________________________ 
 
16) QUANTO SI E’ SENTITA STANCA? 
____________________________________________________________ 
 
17) COME SI E’ SENTITA AL RISVEGLIO? 
____________________________________________________________ 
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18) QUANTO SI E’ SENTITA RIGIDA? 
____________________________________________________________ 
 
19) QUANTO SI E’ SENTITA ANSIOSA  O NERVOSA? 
____________________________________________________________ 
 
20) QUANTO SI E’ SENTITA DEPRESSA O TRISTE? 
____________________________________________________________ 
